GA-binding	B-protein
protein	I-protein
factors	I-protein
,	O
in	O
concert	O
with	O
the	O
coactivator	B-protein
CREB	I-protein
binding	I-protein
protein/p300	I-protein
,	O
control	O
the	O
induction	O
of	O
the	O
interleukin	B-DNA
16	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Interleukin	B-protein
16	I-protein
(	O
IL-16	B-protein
)	O
is	O
a	O
chemotactic	B-protein
cytokine	I-protein
that	O
binds	O
to	O
the	O
CD4	B-protein
receptor	I-protein
and	O
affects	O
the	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
and	O
replication	O
of	O
HIV	O
.	O

It	O
is	O
expressed	O
as	O
a	O
large	O
67-kDa	B-protein
precursor	I-protein
protein	I-protein
(	O
pro-IL-16	B-protein
)	O
in	O
lymphocytes	B-cell_type
,	O
macrophages	B-cell_type
,	O
and	O
mast	B-cell_type
cells	I-cell_type
,	O
as	O
well	O
as	O
in	O
airway	B-cell_type
epithelial	I-cell_type
cells	I-cell_type
from	O
asthmatics	O
after	O
challenge	O
with	O
allergen	O
.	O

This	O
pro-IL-16	B-protein
is	O
subsequently	O
processed	O
to	O
the	O
mature	O
cytokine	O
of	O
13	B-protein
kDa	I-protein
.	O

To	O
study	O
the	O
expression	O
of	O
IL-16	B-protein
at	O
the	O
transcriptional	O
level	O
,	O
we	O
cloned	O
the	O
human	B-DNA
chromosomal	I-DNA
IL-16	I-DNA
gene	I-DNA
and	O
analyzed	O
its	O
promoter	O
.	O

The	O
human	B-DNA
IL-16	I-DNA
gene	I-DNA
consists	O
of	O
seven	O
exons	B-DNA
and	O
six	O
introns	B-DNA
.	O

The	O
5	B-DNA
'	I-DNA
sequences	I-DNA
up	O
to	O
nucleotide	O
-120	O
of	O
the	O
human	O
and	O
murine	O
IL-16	B-protein
genes	O
share	O
>	O
84	O
%	O
sequence	O
homology	O
and	O
harbor	B-DNA
promoter	I-DNA
elements	I-DNA
for	O
constitutive	O
and	O
inducible	O
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Although	O
both	O
promoters	O
lack	O
any	O
TATA	B-DNA
box	I-DNA
,	O
they	O
contain	O
two	O
CAAT	B-DNA
box-like	I-DNA
motifs	I-DNA
and	O
three	O
binding	B-DNA
sites	I-DNA
of	O
GA-binding	B-protein
protein	I-protein
(	I-protein
GABP	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
.	O

Two	O
of	O
these	O
motifs	O
are	O
part	O
of	O
a	O
highly	O
conserved	O
and	O
inducible	O
dyad	B-DNA
symmetry	I-DNA
element	I-DNA
shown	O
previously	O
to	O
control	O
a	O
remote	O
IL-2	B-DNA
enhancer	I-DNA
and	O
the	O
CD18	B-DNA
promoter	I-DNA
.	O

In	O
concert	O
with	O
the	O
coactivator	B-protein
CREB	I-protein
binding	I-protein
protein/p300	I-protein
,	O
which	O
interacts	O
with	O
GABPalpha	B-protein
,	O
the	O
binding	O
of	O
GABPalpha	B-protein
and	O
-beta	B-protein
to	O
the	O
dyad	B-DNA
symmetry	I-DNA
element	I-DNA
controls	O
the	O
induction	O
of	O
IL-16	B-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

Supplementing	O
the	O
data	O
on	O
the	O
processing	O
of	O
pro-IL-16	B-protein
,	O
our	O
results	O
indicate	O
the	O
complexity	O
of	O
IL-16	B-protein
expression	O
,	O
which	O
is	O
tightly	O
controlled	O
at	O
the	O
transcriptional	O
and	O
posttranslational	O
levels	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

96	NULL
,	NULL
pp	NULL
.	NULL

1541-1546	NULL
,	NULL
February	NULL
1999	NULL
Immunology	NULL
GA-binding	NULL
protein	NULL
factors	NULL
,	NULL
in	NULL
concert	NULL
with	NULL
the	NULL
coactivator	NULL
CREB	NULL
binding	NULL
protein/p300	NULL
,	NULL
control	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
interleukin	NULL
16	NULL
promoter	NULL
in	NULL
T	NULL
lymphocytes	NULL
NoRBERT	NULL
BANNERT*T	NULL
,	NULL
Avorst	NULL
?	NULL

,	NULL
MicHaEL	NULL
BaIER*§	NULL
,	NULL
EpoarR	NULL
AND	NULL
REINHARD	NULL
KURTH*	NULL
*Paul-Ehrlich-Institute	NULL
,	NULL
Paul-Ebrlich-Strasse	NULL
51-59	NULL
,	NULL
D-63225	NULL
Langen	NULL
,	NULL
Germany	NULL
;	NULL
and	NULL
*Department	NULL
of	NULL
Molecular	NULL
Pathology	NULL
,	NULL
Institute	NULL
of	NULL
Pathology	NULL
,	NULL
University	NULL
of	NULL
Wiirzburg	NULL
,	NULL
Josef-Schneider-Strasse	NULL
2	NULL
,	NULL
D-97080	NULL
Wiirzburg	NULL
,	NULL
Germany	NULL
Communicated	NULL
by	NULL
Maurice	NULL
R.	NULL
Hilleman	NULL
,	NULL
Merck	NULL
and	NULL
Co.	NULL
,	NULL
Inc	NULL
,	NULL
West	NULL
Point	NULL
,	NULL
PA	NULL
,	NULL
December	NULL
17	NULL
,	NULL
1998	NULL
(	NULL
received	NULL
for	NULL
review	NULL
October	NULL
28	NULL
,	NULL
1998	NULL
)	NULL
ABSTRACT	NULL
Interleukin	NULL
16	NULL
(	NULL
IL-16	NULL
)	NULL
is	NULL
a	NULL
chemotactic	NULL
cytokine	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
CD4	NULL
receptor	NULL
and	NULL
affects	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
and	NULL
replication	NULL
of	NULL
HIV	NULL
.	NULL

It	NULL
is	NULL
expressed	NULL
as	NULL
a	NULL
large	NULL
67-kDa	NULL
precursor	NULL
protein	NULL
(	NULL
pro-IL-16	NULL
)	NULL
in	NULL
lymphocytes	NULL
,	NULL
mac-rophages	NULL
,	NULL
and	NULL
mast	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
airway	NULL
epithelial	NULL
cells	NULL
from	NULL
asthmatics	NULL
after	NULL
challenge	NULL
with	NULL
allergen	NULL
.	NULL

This	NULL
pro-IL-16	NULL
is	NULL
subsequently	NULL
processed	NULL
to	NULL
the	NULL
mature	NULL
cytokine	NULL
of	NULL
13	NULL
kDa	NULL
.	NULL

To	NULL
study	NULL
the	NULL
expression	NULL
of	NULL
IL-16	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
,	NULL
we	NULL
cloned	NULL
the	NULL
human	NULL
chromosomal	NULL
IL-16	NULL
gene	NULL
and	NULL
analyzed	NULL
its	NULL
promoter	NULL
.	NULL

The	NULL
human	NULL
IL-16	NULL
gene	NULL
consists	NULL
of	NULL
seven	NULL
exons	NULL
and	NULL
six	NULL
introns	NULL
.	NULL

The	NULL
5	NULL
sequences	NULL
up	NULL
to	NULL
nucleotide	NULL
-120	NULL
of	NULL
the	NULL
human	NULL
and	NULL
murine	NULL
IL-16	NULL
genes	NULL
share	NULL
>	NULL
84	NULL
%	NULL
sequence	NULL
homol-ogy	NULL
and	NULL
harbor	NULL
promoter	NULL
elements	NULL
for	NULL
constitutive	NULL
and	NULL
inducible	NULL
transcription	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Although	NULL
both	NULL
promoters	NULL
lack	NULL
any	NULL
TATA	NULL
box	NULL
,	NULL
they	NULL
contain	NULL
two	NULL
CAAT	NULL
box-like	NULL
motifs	NULL
and	NULL
three	NULL
binding	NULL
sites	NULL
of	NULL
GA-binding	NULL
protein	NULL
(	NULL
GABP	NULL
)	NULL
transcription	NULL
factors	NULL
.	NULL

Two	NULL
of	NULL
these	NULL
motifs	NULL
are	NULL
part	NULL
of	NULL
a	NULL
highly	NULL
conserved	NULL
and	NULL
inducible	NULL
dyad	NULL
symmetry	NULL
element	NULL
shown	NULL
previously	NULL
to	NULL
control	NULL
a	NULL
remote	NULL
IL-2	NULL
enhancer	NULL
and	NULL
the	NULL
CD18	NULL
promoter	NULL
.	NULL

In	NULL
concert	NULL
with	NULL
the	NULL
coactivator	NULL
CREB	NULL
binding	NULL
protein/p300	NULL
,	NULL
which	NULL
interacts	NULL
with	NULL
GABPa	NULL
,	NULL
the	NULL
binding	NULL
of	NULL
GABPa	NULL
and	NULL
-	NULL
to	NULL
the	NULL
dyad	NULL
symmetry	NULL
element	NULL
controls	NULL
the	NULL
induction	NULL
of	NULL
IL-16	NULL
promoter	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Supplementing	NULL
the	NULL
data	NULL
on	NULL
the	NULL
processing	NULL
of	NULL
pro-IL-16	NULL
,	NULL
our	NULL
results	NULL
indicate	NULL
the	NULL
complexity	NULL
of	NULL
IL-16	NULL
expression	NULL
,	NULL
which	NULL
is	NULL
tightly	NULL
controlled	NULL
at	NULL
the	NULL
transcriptional	NULL
and	NULL
posttranslational	NULL
levels	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Interleukin	NULL
16	NULL
(	NULL
IL-16	NULL
)	NULL
,	NULL
originally	NULL
identified	NULL
in	NULL
supernatants	NULL
of	NULL
mitogen-activated	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
(	NULL
1	NULL
)	NULL
,	NULL
is	NULL
synthesized	NULL
as	NULL
a	NULL
large	NULL
67-kDa	NULL
precursor	NULL
protein	NULL
(	NULL
2-4	NULL
)	NULL
.	NULL

This	NULL
pro-IL-16	NULL
is	NULL
almost	NULL
exclusively	NULL
expressed	NULL
in	NULL
lymphatic	NULL
tissues	NULL
(	NULL
4	NULL
)	NULL
and	NULL
contains	NULL
three	NULL
postsynaptic	NULL
density	NULL
protein	NULL
,	NULL
disc-large	NULL
,	NULL
zonulin-1	NULL
(	NULL
PDZ	NULL
)	NULL
domains	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
modules	NULL
involved	NULL
in	NULL
protein-protein	NULL
interactions	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
.	NULL

The	NULL
maturation	NULL
of	NULL
pro-IL-16	NULL
appears	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
caspase	NULL
3	NULL
leading	NULL
to	NULL
the	NULL
bioactive	NULL
IL-16	NULL
,	NULL
which	NULL
consists	NULL
of	NULL
the	NULL
C-terminal	NULL
121	NULL
amino	NULL
acids	NULL
of	NULL
the	NULL
precursor	NULL
(	NULL
4	NULL
,	NULL
7	NULL
)	NULL
.	NULL

Activated	NULL
CD8	NULL
*	NULL
and	NULL
CD4*	NULL
T	NULL
cells	NULL
synthesize	NULL
identical	NULL
levels	NULL
of	NULL
IL-16	NULL
transcripts	NULL
,	NULL
but	NULL
mature	NULL
IL-16	NULL
is	NULL
predominantly	NULL
secreted	NULL
by	NULL
CD8+*	NULL
T	NULL
lymphocytes	NULL
in	NULL
response	NULL
to	NULL
antigens	NULL
,	NULL
histamine	NULL
,	NULL
or	NULL
serotonin	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

In	NULL
addi-tion	NULL
,	NULL
human	NULL
mast	NULL
cells	NULL
also	NULL
synthesize	NULL
pro-IL-16	NULL
,	NULL
and	NULL
treatment	NULL
with	NULL
anaphylatoxin	NULL
,	NULL
C5a	NULL
,	NULL
or	NULL
12-O-tetradecanoylphorbol-13-acetate	NULL
(	NULL
TPA	NULL
)	NULL
increases	NULL
the	NULL
IL-16	NULL
mRNA	NULL
level	NULL
as	NULL
much	NULL
as	NULL
10-fold	NULL
(	NULL
10	NULL
)	NULL
.	NULL

IL-16	NULL
binds	NULL
to	NULL
the	NULL
CD4	NULL
receptor	NULL
and	NULL
is	NULL
therefore	NULL
selectively	NULL
active	NULL
on	NULL
CD4*	NULL
T	NULL
lymphocytes	NULL
,	NULL
monocytes	NULL
,	NULL
and	NULL
eosinophils	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

Like	NULL
other	NULL
cytokines	NULL
,	NULL
IL-16	NULL
exerts	NULL
numerous	NULL
and	NULL
partially	NULL
contradictory	NULL
effects	NULL
in	NULL
vitro	NULL
.	NULL

Although	NULL
it	NULL
is	NULL
able	NULL
to	NULL
render	NULL
CD4*	NULL
T	NULL
cells	NULL
unresponsive	NULL
to	NULL
TCR/CD3	NULL
stimuli	NULL
,	NULL
it	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

PNAS	NULL
is	NULL
available	NULL
online	NULL
at	NULL
www.pnas.org	NULL
.	NULL

1541	NULL
induces	NULL
the	NULL
expression	NULL
of	NULL
certain	NULL
activation	NULL
markers	NULL
,	NULL
such	NULL
as	NULL
IL-2	NULL
receptor	NULL
subunits	NULL
(	NULL
13	NULL
)	NULL
.	NULL

The	NULL
proliferative	NULL
response	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
cotreated	NULL
with	NULL
IL-16	NULL
and	NULL
IL-2	NULL
for	NULL
long	NULL
periods	NULL
is	NULL
therefore	NULL
selectively	NULL
enhanced	NULL
(	NULL
14	NULL
)	NULL
,	NULL
suggesting	NULL
the	NULL
possible	NULL
use	NULL
of	NULL
IL-16	NULL
as	NULL
an	NULL
immune	NULL
therapy	NULL
to	NULL
counteract	NULL
conditions	NULL
of	NULL
CD4*	NULL
T	NULL
cell	NULL
deficiency	NULL
such	NULL
as	NULL
that	NULL
associated	NULL
with	NULL
AIDS	NULL
.	NULL

Moreover	NULL
,	NULL
IL-16	NULL
inhibits	NULL
the	NULL
replication	NULL
of	NULL
T	NULL
cell	NULL
and	NULL
mono-cyte	NULL
tropic	NULL
HIV	NULL
strains	NULL
in	NULL
vitro	NULL
(	NULL
15-17	NULL
)	NULL
.	NULL

HIV	NULL
patients	NULL
receiving	NULL
anti-retroviral	NULL
therapy	NULL
display	NULL
rapidly	NULL
increasing	NULL
IL-16	NULL
serum	NULL
levels	NULL
,	NULL
possibly	NULL
reflecting	NULL
the	NULL
recovery	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
the	NULL
reduced	NULL
viral	NULL
load	NULL
(	NULL
18	NULL
)	NULL
.	NULL

To	NULL
learn	NULL
more	NULL
about	NULL
the	NULL
expression	NULL
of	NULL
IL-16	NULL
,	NULL
we	NULL
have	NULL
determined	NULL
the	NULL
genomic	NULL
organization	NULL
of	NULL
the	NULL
human	NULL
IL-16	NULL
gene	NULL
,	NULL
including	NULL
the	NULL
structure	NULL
and	NULL
function	NULL
of	NULL
its	NULL
promoter	NULL
.	NULL

A	NULL
DNA	NULL
fragment	NULL
spanning	NULL
the	NULL
nucleotides	NULL
from	NULL
-408	NULL
to	NULL
+88	NULL
of	NULL
the	NULL
IL-16	NULL
gene	NULL
was	NULL
found	NULL
to	NULL
exert	NULL
constitutive	NULL
promoter	NULL
activity	NULL
in	NULL
lymphoid	NULL
and	NULL
nonlymphoid	NULL
cells	NULL
.	NULL

A	NULL
strong	NULL
inducible	NULL
promoter	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
was	NULL
identified	NULL
within	NULL
the	NULL
immediate	NULL
5	NULL
'	NULL
upstream	NULL
DNA	NULL
of	NULL
approximately	NULL
90	NULL
bp	NULL
.	NULL

Although	NULL
this	NULL
promoter	NULL
fragment	NULL
lacks	NULL
any	NULL
TATA	NULL
box-like	NULL
sequence	NULL
element	NULL
,	NULL
it	NULL
contains	NULL
three	NULL
binding	NULL
sites	NULL
for	NULL
Ets-like	NULL
proteins	NULL
.	NULL

One	NULL
of	NULL
these	NULL
fragments	NULL
overlaps	NULL
with	NULL
the	NULL
previously	NULL
reported	NULL
transcriptional	NULL
start	NULL
sites	NULL
(	NULL
4	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
other	NULL
two	NULL
sites	NULL
generate	NULL
a	NULL
dyad	NULL
symmetry	NULL
element	NULL
(	NULL
DSE	NULL
)	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
these	NULL
sites	NULL
are	NULL
bound	NULL
by	NULL
GA-binding	NULL
protein	NULL
(	NULL
GABP	NULL
)	NULL
factors	NULL
which	NULL
,	NULL
in	NULL
concert	NULL
with	NULL
the	NULL
coactivators	NULL
CREB	NULL
binding	NULL
protein	NULL
(	NULL
CBP	NULL
)	NULL
/p300	NULL
,	NULL
appear	NULL
to	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
control	NULL
of	NULL
the	NULL
IL-16	NULL
promoter	NULL
.	NULL

CBP/p300	NULL
binds	NULL
to	NULL
GABPa	NULL
and	NULL
enhances	NULL
strongly	NULL
the	NULL
GABP	NULL
mediated	NULL
IL-16	NULL
promoter	NULL
induction	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
Culture	NULL
,	NULL
DNA	NULL
Transfections	NULL
,	NULL
and	NULL
Reporter	NULL
Gene	NULL
As-says	NULL
.	NULL

Human	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
,	NULL
and	NULL
HeLa	NULL
cells	NULL
and	NULL
293	NULL
embryonic	NULL
kidney	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
DMEM	NULL
medium	NULL
.	NULL

Both	NULL
media	NULL
were	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

DNA	NULL
transfections	NULL
were	NULL
performed	NULL
by	NULL
using	NULL
the	NULL
SuperFect	NULL
transfection	NULL
reagent	NULL
(	NULL
Qiagen	NULL
,	NULL
Chats-worth	NULL
,	NULL
CA	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturers	NULL
protocol	NULL
.	NULL

293	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
using	NULL
a	NULL
conventional	NULL
calcium	NULL
phosphate	NULL
coprecipitation	NULL
technique	NULL
.	NULL

Luciferase	NULL
assays	NULL
were	NULL
performed	NULL
by	NULL
using	NULL
the	NULL
Luciferase	NULL
Assay	NULL
Reagent	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

As	NULL
transfection	NULL
controls	NULL
,	NULL
the	NULL
pSEAP2-control	NULL
plasmid	NULL
(	NULL
CLONTECH	NULL
)	NULL
Abbreviations	NULL
:	NULL
Ab	NULL
,	NULL
antibody	NULL
;	NULL
CBP	NULL
,	NULL
CREB	NULL
binding	NULL
protein	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility-shift	NULL
assay	NULL
;	NULL
PBMC	NULL
,	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
;	NULL
PDZ	NULL
,	NULL
postsynaptic	NULL
density	NULL
protein	NULL
,	NULL
disc-large	NULL
,	NULL
zonulin-1	NULL
;	NULL
TPA	NULL
,	NULL
12-O-tetradecanoylphorbol-13-acetate	NULL
;	NULL
DSE	NULL
,	NULL
dyad	NULL
symmetry	NULL
clement	NULL
;	NULL
ERE	NULL
,	NULL
Ets-related	NULL
element	NULL
;	NULL
IL	NULL
,	NULL
interleukin	NULL
.	NULL

Data	NULL
deposition	NULL
:	NULL
The	NULL
sequences	NULL
reported	NULL
in	NULL
this	NULL
paper	NULL
have	NULL
been	NULL
submitted	NULL
to	NULL
the	NULL
GenBank	NULL
database	NULL
[	NULL
accession	NULL
nos	NULL
.	NULL

AFO77011	NULL
(	NULL
human	NULL
IL-16	NULL
gene	NULL
and	NULL
promoter	NULL
)	NULL
and	NULL
AFO77012	NULL
(	NULL
murine	NULL
IL-16	NULL
promoter	NULL
)	NULL
]	NULL
.	NULL

TN.B	NULL
.	NULL

and	NULL
A.A.	NULL
contributed	NULL
equally	NULL
to	NULL
this	NULL
work	NULL
.	NULL

$	NULL
To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

e-mail	NULL
:	NULL
baieem	NULL
@	NULL
rki.de	NULL
.	NULL

1542	NULL
Immunology	NULL
:	NULL
Bannert	NULL
et	NULL
al	NULL
.	NULL

was	NULL
cotransfected	NULL
and	NULL
assays	NULL
were	NULL
performed	NULL
by	NULL
using	NULL
the	NULL
Great	NULL
EscAPe	NULL
SEAP	NULL
chemiluminescence	NULL
detection	NULL
kit	NULL
(	NULL
CLONTECH	NULL
)	NULL
.	NULL

Recombinant	NULL
DNA	NULL
Work	NULL
and	NULL
Sequence	NULL
Analysis	NULL
.	NULL

Overlapping	NULL
human	NULL
IL-16	NULL
gene	NULL
fragments	NULL
were	NULL
amplified	NULL
by	NULL
using	NULL
human	NULL
PBMC	NULL
DNA	NULL
,	NULL
the	NULL
Tth-Polymerase	NULL
Mix	NULL
(	NULL
CLONTECH	NULL
)	NULL
,	NULL
and	NULL
the	NULL
following	NULL
primer	NULL
pairs	NULL
:	NULL
(	NULL
5'-CTGCTGCTACCACAG-GAAGACACAGCAG-3	NULL
'	NULL
and	NULL
5-GAGCTGATTCTCTGC-CTGATGGA-3	NULL
'	NULL
;	NULL
5-GAGCACCTAGGATCACACATC-3	NULL
'	NULL
and	NULL
5'-CAGAGCTGAGAGAATATACAGAGGGTC-3	NULL
'	NULL
and	NULL
5'-TTCTAGATCTGCTCCTCCTGCCAAGCT-3	NULL
'	NULL
;	NULL
CACCATCTTACACAAGGAG-3	NULL
'	NULL
and	NULL
TGCAGAGGCTGAGGCTGCAG-3	NULL
'	NULL
;	NULL
5	NULL
``	NULL
-CACAGAGTGTT-TCCAAATGGGCTGGCC-3	NULL
'	NULL
and	NULL
5'-AGCTGTGTGT-GTTATTGGCTTTGGCTTC-3	NULL
'	NULL
;	NULL
5-ACCACAGCTGCTG-GAGACTCCTAG-3	NULL
'	NULL
and	NULL
5-GTGGTAAGTAGTAGCAAT-TTTATTTGATAC-3	NULL
'	NULL
)	NULL
The	NULL
amplification	NULL
products	NULL
were	NULL
cloned	NULL
in	NULL
the	NULL
pGEM-T-vector	NULL
(	NULL
Promega	NULL
)	NULL
and	NULL
sequenced	NULL
.	NULL

To	NULL
minimize	NULL
sequencing	NULL
errors	NULL
,	NULL
multiple	NULL
clones	NULL
were	NULL
sequenced	NULL
for	NULL
every	NULL
fragment	NULL
.	NULL

For	NULL
the	NULL
cloning	NULL
of	NULL
the	NULL
chromosomal	NULL
DNA	NULL
upstream	NULL
of	NULL
the	NULL
human	NULL
IL-16	NULL
cDNA-sequence	NULL
two	NULL
cDNA	NULL
based	NULL
reverse-complementary	NULL
primers	NULL
,	NULL
hGSP1	NULL
:	NULL
5-TCTTCTCCACCCTG-GCTCGCCCTCTGT-3	NULL
'	NULL
and	NULL
hGSP2	NULL
:	NULL
S	NULL
!	NULL

-ACTTGGTCTGT-GGGCCGATACCAGGT-3	NULL
'	NULL
,	NULL
were	NULL
used	NULL
in	NULL
a	NULL
nested	NULL
PCR	NULL
with	NULL
parts	NULL
of	NULL
the	NULL
human	NULL
PromoterFinder	NULL
DNA	NULL
Walking	NULL
kit	NULL
(	NULL
CLONTECH	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
protocol	NULL
.	NULL

Fragments	NULL
of	NULL
1.7	NULL
kb	NULL
(	NULL
Drel	NULL
library	NULL
)	NULL
and	NULL
1.9	NULL
kb	NULL
(	NULL
Pvull	NULL
library	NULL
)	NULL
were	NULL
amplified	NULL
and	NULL
cloned	NULL
in	NULL
pGEM-T.	NULL
Sequencing	NULL
revealed	NULL
the	NULL
expected	NULL
62	NULL
bp	NULL
of	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
IL-16	NULL
cDNA	NULL
sequence	NULL
(	NULL
4	NULL
)	NULL
upstream	NULL
of	NULL
the	NULL
GSP2	NULL
binding	NULL
site	NULL
,	NULL
proving	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
PCRs	NULL
.	NULL

In	NULL
the	NULL
same	NULL
way	NULL
,	NULL
by	NULL
using	NULL
the	NULL
murine	NULL
IL-16	NULL
cDNA-specific	NULL
reverse-complementary	NULL
primers	NULL
mGSP1	NULL
:	NULL
5'-GGCACTCCTCCTTGACTCTCCTTCTGA-3	NULL
'	NULL
and	NULL
mGSP2	NULL
:	NULL
5'-TGAAGTCTGCGTGCTGGCTGCAGGTC-3	NULL
'	NULL
along	NULL
with	NULL
the	NULL
murine	NULL
PromoterFinder	NULL
DNA	NULL
Walking	NULL
kit	NULL
(	NULL
CLONTECH	NULL
)	NULL
,	NULL
a	NULL
1.2-kb	NULL
genomic	NULL
fragment	NULL
(	NULL
Sspl-library	NULL
)	NULL
containing	NULL
the	NULL
sequence	NULL
upstream	NULL
of	NULL
the	NULL
known	NULL
cDNA	NULL
(	NULL
19	NULL
)	NULL
and	NULL
52	NULL
bp	NULL
of	NULL
its	NULL
5'-end	NULL
was	NULL
amplified	NULL
.	NULL

For	NULL
the	NULL
construction	NULL
of	NULL
the	NULL
promoter/reporter	NULL
gene	NULL
plas-mids	NULL
the	NULL
genomic	NULL
fragment	NULL
from	NULL
-1048	NULL
to	NULL
+88	NULL
was	NULL
amplified	NULL
by	NULL
using	NULL
primers	NULL
P1	NULL
:	NULL
GAAGCCTGCAGCCATGTC-3	NULL
'	NULL
,	NULL
and	NULL
P2	NULL
:	NULL
TATCTCGAGCTTGGTCTGTGGGGCGATACCAGGT-3	NULL
'	NULL
and	NULL
human	NULL
DNA	NULL
from	NULL
PBMCs	NULL
as	NULL
template	NULL
.	NULL

The	NULL
PCR	NULL
product	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
pGL3-Basic	NULL
vector	NULL
(	NULL
Promega	NULL
)	NULL
and	NULL
sequenced	NULL
.	NULL

Using	NULL
this	NULL
plasmid	NULL
as	NULL
template	NULL
,	NULL
the	NULL
subfragments	NULL
-408/+88	NULL
,	NULL
-133/+88	NULL
,	NULL
-90/+88	NULL
,	NULL
-408/+3	NULL
,	NULL
-408/-110	NULL
were	NULL
amplified	NULL
and	NULL
cloned	NULL
in	NULL
pGL-3-Basic	NULL
.	NULL

All	NULL
clonings	NULL
were	NULL
verified	NULL
by	NULL
sequencing	NULL
.	NULL

GG-to-CC	NULL
changes	NULL
within	NULL
the	NULL
ERE	NULL
(	NULL
Ets-related	NULL
element	NULL
)	NULL
-C	NULL
and	NULL
-D	NULL
motifs	NULL
and	NULL
the	NULL
+12	NULL
GABP-binding	NULL
site	NULL
were	NULL
introduced	NULL
into	NULL
the	NULL
-408/+88	NULL
promoter	NULL
fragment	NULL
by	NULL
using	NULL
the	NULL
QuikChange	NULL
site-directed	NULL
mutagenesis	NULL
system	NULL
(	NULL
Stratagene	NULL
)	NULL
.	NULL

Electrophoretic	NULL
Mobility-Shift	NULL
Assays	NULL
(	NULL
EMSAs	NULL
)	NULL
.	NULL

EMSAs	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
20	NULL
)	NULL
by	NULL
using	NULL
2	NULL
pg	NULL
of	NULL
nuclear	NULL
protein	NULL
and	NULL
0.5	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
.	NULL

In	NULL
supershift	NULL
EMSAs	NULL
,	NULL
1	NULL
ug	NULL
of	NULL
antibodies	NULL
(	NULL
Abs	NULL
)	NULL
raised	NULL
against	NULL
GABP	NULL
«	NULL
,	NULL
B	NULL
(	NULL
21	NULL
)	NULL
or	NULL
PU.1	NULL
(	NULL
20	NULL
)	NULL
were	NULL
added	NULL
to	NULL
the	NULL
incubations	NULL
.	NULL

When	NULL
the	NULL
DNA	NULL
binding	NULL
of	NULL
recombinant	NULL
GABP	NULL
was	NULL
tested	NULL
,	NULL
2.5-20	NULL
ng	NULL
of	NULL
bacterially	NULL
expressed	NULL
proteins	NULL
prepared	NULL
as	NULL
described	NULL
(	NULL
21	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
EMSAs	NULL
.	NULL

Interaction	NULL
Between	NULL
GABPs	NULL
and	NULL
p300	NULL
.	NULL

Five	NULL
micrograms	NULL
of	NULL
bacterially	NULL
expressed	NULL
GST	NULL
/p300	NULL
fusion	NULL
proteins	NULL
was	NULL
immobilized	NULL
on	NULL
glutathione	NULL
agarose	NULL
beads	NULL
(	NULL
30	NULL
ul	NULL
)	NULL
and	NULL
incubated	NULL
with	NULL
50	NULL
ng	NULL
of	NULL
bacterially	NULL
expressed	NULL
full-size	NULL
GABPa	NULL
,	NULL
-B	NULL
or	NULL
-	NULL
«	NULL
+B	NULL
(	NULL
21	NULL
)	NULL
in	NULL
500	NULL
pl	NULL
of	NULL
binding	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
Tris-Cl	NULL
,	NULL
pH	NULL
7.8/75	NULL
mM	NULL
NaCl1/0.5	NULL
mM	NULL
EDTA/O0.5	NULL
mM	NULL
EGTA/S5	NULL
mM	NULL
NaF/0.5	NULL
mM	NULL
DTT/20	NULL
mM	NULL
leupeptin/0.2	NULL
mM	NULL
AMSF/0.5	NULL
%	NULL
nonfat	NULL
dry	NULL
milk	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
as	NULL
blocker	NULL
)	NULL
.	NULL

After	NULL
rotating	NULL
for	NULL
2	NULL
h	NULL
at	NULL
4°C	NULL
and	NULL
extensive	NULL
washings	NULL
with	NULL
the	NULL
binding	NULL
buffer	NULL
,	NULL
bound	NULL
proteins	NULL
were	NULL
eluted	NULL
by	NULL
boiling	NULL
in	NULL
Laemmli	NULL
sample	NULL
buffer	NULL
,	NULL
fractionated	NULL
on	NULL
a	NULL
12.5	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
,	NULL
and	NULL
immunodetected	NULL
by	NULL
using	NULL
GABPa+	NULL
-specific	NULL
Abs	NULL
.	NULL

RESULTS	NULL
Organization	NULL
of	NULL
the	NULL
Human	NULL
IL-16	NULL
Gene	NULL
.	NULL

For	NULL
the	NULL
analysis	NULL
of	NULL
the	NULL
chromosomal	NULL
IL-16	NULL
gene	NULL
,	NULL
overlapping	NULL
genomic	NULL
DNA	NULL
fragments	NULL
from	NULL
human	NULL
PBMCs	NULL
were	NULL
amplified	NULL
by	NULL
using	NULL
IL-16	NULL
cDNA-specific	NULL
primer	NULL
pairs	NULL
and	NULL
sequenced	NULL
.	NULL

The	NULL
human	NULL
IL-16	NULL
gene	NULL
spans	NULL
approximately	NULL
12.8	NULL
kb	NULL
and	NULL
consists	NULL
of	NULL
seven	NULL
exons	NULL
and	NULL
six	NULL
introns	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Exon	NULL
I	NULL
contains	NULL
the	NULL
largest	NULL
part	NULL
of	NULL
the	NULL
-untranslated	NULL
mRNA	NULL
region	NULL
.	NULL

The	NULL
first	NULL
ATG	NULL
,	NULL
which	NULL
corresponds	NULL
to	NULL
the	NULL
translational	NULL
start	NULL
codon	NULL
(	NULL
4	NULL
)	NULL
,	NULL
starts	NULL
on	NULL
nucleotide	NULL
position	NULL
51	NULL
of	NULL
exon	NULL
II	NULL
.	NULL

This	NULL
exon	NULL
is	NULL
unusually	NULL
long	NULL
(	NULL
1096	NULL
bp	NULL
)	NULL
,	NULL
encoding	NULL
348	NULL
aa	NULL
harboring	NULL
the	NULL
proline-rich	NULL
part	NULL
and	NULL
the	NULL
N-terminal	NULL
region	NULL
of	NULL
the	NULL
first	NULL
PDZ	NULL
domain	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Exon	NULL
III	NULL
and	NULL
the	NULL
first	NULL
nucleotides	NULL
of	NULL
exon	NULL
IV	NULL
code	NULL
for	NULL
the	NULL
remainder	NULL
of	NULL
the	NULL
first	NULL
PDZ	NULL
domain	NULL
.	NULL

PDZ-2	NULL
is	NULL
encoded	NULL
by	NULL
the	NULL
exons	NULL
IV	NULL
and	NULL
V.	NULL
Exons	NULL
VI	NULL
and	NULL
VII	NULL
contain	NULL
the	NULL
sequence	NULL
for	NULL
PDZ-3	NULL
(	NULL
found	NULL
in	NULL
mature	NULL
IL-16	NULL
)	NULL
.	NULL

The	NULL
cleavage	NULL
site	NULL
for	NULL
the	NULL
putative	NULL
processing	NULL
enzyme	NULL
caspase	NULL
3	NULL
is	NULL
encoded	NULL
in	NULL
exon	NULL
V.	NULL
Characterization	NULL
of	NULL
the	NULL
IL-16	NULL
Promoter	NULL
.	NULL

Fig	NULL
.	NULL

2	NULL
shows	NULL
a	NULL
sequence	NULL
comparison	NULL
between	NULL
the	NULL
5'-flanking	NULL
regions	NULL
of	NULL
human	NULL
and	NULL
murine	NULL
IL-16	NULL
genes	NULL
spanning	NULL
the	NULL
nucleotides	NULL
from	NULL
position	NULL
-440	NULL
to	NULL
+130	NULL
.	NULL

The	NULL
5'-untranslated	NULL
mRNA	NULL
regions	NULL
and	NULL
the	NULL
immediate	NULL
upstream	NULL
regions	NULL
(	NULL
up	NULL
to	NULL
-120	NULL
)	NULL
from	NULL
both	NULL
genes	NULL
share	NULL
a	NULL
high	NULL
sequence	NULL
homology	NULL
,	NULL
suggesting	NULL
their	NULL
functional	NULL
importance	NULL
.	NULL

Multiple	NULL
transcriptional	NULL
initiation	NULL
sites	NULL
have	NULL
been	NULL
identified	NULL
within	NULL
40	NULL
bp	NULL
5	NULL
'	NULL
of	NULL
the	NULL
murine	NULL
and	NULL
human	NULL
IL-16	NULL
genes	NULL
(	NULL
4	NULL
,	NULL
19	NULL
)	NULL
from	NULL
which	NULL
the	NULL
most	NULL
upstream	NULL
site	NULL
of	NULL
human	NULL
IL-16	NULL
gene	NULL
was	NULL
assigned	NULL
to	NULL
be	NULL
position	NULL
+1	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Accordingly	NULL
,	NULL
neither	NULL
the	NULL
human	NULL
nor	NULL
murine	NULL
IL-16	NULL
gene	NULL
contains	NULL
a	NULL
canonical	NULL
TATA	NULL
box	NULL
.	NULL

CAAT	NULL
box	NULL
motifs	NULL
are	NULL
present	NULL
at	NULL
the	NULL
positions	NULL
-98	NULL
and	NULL
-118	NULL
,	NULL
and	NULL
at	NULL
+12	NULL
,	NULL
-25	NULL
,	NULL
and	NULL
-39	NULL
of	NULL
both	NULL
genes	NULL
three	NULL
sites	NULL
are	NULL
located	NULL
for	NULL
the	NULL
putative	NULL
binding	NULL
of	NULL
Ets-like	NULL
transcription	NULL
factors	NULL
.	NULL

The	NULL
Ets	NULL
elements	NULL
at	NULL
+12	NULL
and	NULL
-25	NULL
of	NULL
the	NULL
human	NULL
gene	NULL
form	NULL
a	NULL
direct	NULL
repeat	NULL
of	NULL
11	NULL
bp	NULL
,	NULL
whereas	NULL
in	NULL
both	NULL
genes	NULL
those	NULL
repeats	NULL
around	NULL
-25	NULL
and	NULL
-39	NULL
are	NULL
part	NULL
of	NULL
a	NULL
33	NULL
bp-inverted	NULL
repeat	NULL
.	NULL

A	NULL
very	NULL
similar	NULL
repeat	NULL
designated	NULL
as	NULL
DSE	NULL
was	NULL
recently	NULL
identified	NULL
as	NULL
an	NULL
inducible	NULL
sequence	NULL
element	NULL
of	NULL
a	NULL
distal	NULL
IL-2	NULL
enhancer	NULL
(	NULL
20	NULL
)	NULL
.	NULL

To	NULL
test	NULL
the	NULL
IL-16	NULL
promoter	NULL
activity	NULL
,	NULL
a	NULL
DNA	NULL
fragment	NULL
from	NULL
position	NULL
-1048	NULL
to	NULL
+88	NULL
and	NULL
shorter	NULL
subfragments	NULL
were	NULL
cloned	NULL
in	NULL
front	NULL
of	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
and	NULL
transiently	NULL
trans-	NULL
suf	NULL
proline-rich	NULL
UT	NULL
|	NULL
200	NULL
bp	NULL
I	NULL
I	NULL
AAUAAA	NULL
AAUAAA	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Genomic	NULL
organization	NULL
of	NULL
the	NULL
human	NULL
IL-16	NULL
gene	NULL
.	NULL

The	NULL
seven	NULL
exons	NULL
are	NULL
shown	NULL
as	NULL
black	NULL
boxes	NULL
and	NULL
projected	NULL
on	NULL
the	NULL
IL-16	NULL
mRNA	NULL
.	NULL

UT	NULL
,	NULL
untranslated	NULL
5	NULL
'	NULL
and	NULL
3	NULL
'	NULL
sequences	NULL
;	NULL
AAUAAA	NULL
,	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
addition	NULL
motifs	NULL
.	NULL

The	NULL
fragments	NULL
encoding	NULL
the	NULL
proline-rich	NULL
region	NULL
and	NULL
the	NULL
three	NULL
PDZ	NULL
domains	NULL
of	NULL
pro-IL-16	NULL
protein	NULL
are	NULL
indicated	NULL
.	NULL

The	NULL
black	NULL
bar	NULL
below	NULL
denotes	NULL
the	NULL
sequence	NULL
coding	NULL
for	NULL
the	NULL
mature	NULL
IL-16	NULL
protein	NULL
.	NULL

The	NULL
complete	NULL
gene	NULL
of	NULL
approximately	NULL
12.8	NULL
kb	NULL
was	NULL
cloned	NULL
and	NULL
sequenced	NULL
as	NULL
six	NULL
overlapping	NULL
fragments	NULL
depicted	NULL
above	NULL
the	NULL
gene	NULL
structure	NULL
.	NULL

The	NULL
use	NULL
of	NULL
an	NULL
alternative	NULL
splice	NULL
acceptor	NULL
in	NULL
intron	NULL
5	NULL
,	NULL
three	NULL
nucleotides	NULL
downstream	NULL
of	NULL
the	NULL
regular	NULL
site	NULL
,	NULL
generates	NULL
a	NULL
transcript	NULL
with	NULL
a	NULL
missing	NULL
alanine	NULL
codon	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
splice	NULL
acceptor	NULL
is	NULL
predominantly	NULL
used	NULL
in	NULL
mice	NULL
because	NULL
we	NULL
were	NULL
unable	NULL
to	NULL
find	NULL
cDNAs	NULL
encoding	NULL
this	NULL
alanine	NULL
in	NULL
murine	NULL
PBMCs	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Immunology	NULL
:	NULL
Bannert	NULL
et	NULL
al	NULL
.	NULL

-440	NULL
-343	NULL
-249	NULL
-150	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
ACCTTAGGGAACACTAGCTGCCAGGTTTTTTTGCTGCCTTGTTTCTACGCTGCCCTATACCCTCCCGGGEGTGGG-TACTT-CACCACATGC-ACTTGTAA	NULL
K	NULL
k	NULL
o	NULL
Kw	NULL
A	NULL
dk	NULL
h	NULL
fk	NULL
k	NULL
w	NULL
tok	NULL
xo	NULL
kx	NULL
k	NULL
k	NULL
%	NULL
%	NULL
x	NULL
%	NULL
*	NULL
%	NULL
%	NULL
K	NULL
%	NULL
w	NULL
kook	NULL
k	NULL
kok	NULL
k	NULL
kok	NULL
kk	NULL
%	NULL
k	NULL
%	NULL
He	NULL
we	NULL
dak	NULL
ne	NULL
e	NULL
te	NULL
dene	NULL
te	NULL
desk	NULL
k	NULL
sek	NULL
AC-TTAGGCAACATTAGAAGACAG-TTCCCTTG	NULL
--	NULL
GCC	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
CCTG-	NULL
TGTGTA-CCTCCTGGGGTCAGATAGTTTCCCCACATGCCATTTT	NULL
--	NULL
-CTGAAGCAATGCCAGTCCCTCCACACTCAAAGC	NULL
--	NULL
--	NULL
--	NULL
~	NULL
CTTTTGTTCC	NULL
’	NULL
I	NULL
‘	NULL
A	NULL
’	NULL
I	NULL
‘	NULL
CATAAAGAGTCAGGGTCTTCAAGTATGTCAACAGTATGAGCC	NULL
CATGAC	NULL
Sede	NULL
ae	NULL
e	NULL
sk	NULL
ie	NULL
--	NULL
—AAGCAAAGTT	NULL
GTGCTGGCACATTTGT	NULL
’	NULL
I	NULL
‘	NULL
A	NULL
’	NULL
I	NULL
‘	NULL
C	NULL
CCCAGCTC	NULL
’	NULL
I	NULL
‘	NULL
TGTGC	NULL
C	NULL
CATCACAGACAGCCGGTAACTTTCCGT—	NULL
—GTC	NULL
—————	NULL
TATGA	NULL
TGCATG—	NULL
CTGGATACCAGGTTGCTGGAAGTCAAGCGGTGCTCTGCATGTCTAGGAGCTGCTGGCTCTGCCACGTCACGCACCAAGCGAGAAAAGAATCCTCTTTA-CAT	NULL
K	NULL
ake	NULL
ke	NULL
oe	NULL
tk	NULL
de	NULL
Sk	NULL
Hoke	NULL
ce	NULL
cect	NULL
e	NULL
kok	NULL
A	NULL
k	NULL
e	NULL
te	NULL
*	NULL
*	NULL
o	NULL
%	NULL
we	NULL
ck	NULL
ak	NULL
we	NULL
k	NULL
ae	NULL
dk	NULL
k	NULL
%	NULL
kkk	NULL
%	NULL
k	NULL
%	NULL
%	NULL
*	NULL
Hoe	NULL
teak	NULL
tek	NULL
k	NULL
¥	NULL
%	NULL
kk	NULL
K	NULL
k	NULL
ek	NULL
k	NULL
%	NULL
¥	NULL
%	NULL
%	NULL
GTGCACAACAGGTCATTGCAAGCCAAGGGAAACCTGGAACATCTAACAGGCACTAGCTGTAC-A-GCAACATCCCAGGAGGGAAGAGACCCCTTTCTCAT	NULL
GGCTGCTGA	NULL
’	NULL
I	NULL
‘	NULL
GAACTTCTCACTGAAAGCAGCTCAATQTCCGT	NULL
’	NULL
I	NULL
‘	NULL
TTTCCGTCCCAA	NULL
’	NULL
I	NULL
‘	NULL
CAAAGCGTGTCTCGCCTTCTCACAGCTTGAGGCTACCGTTTTGA	NULL
X	NULL
%	NULL
%	NULL
K	NULL
«	NULL
%	NULL
*	NULL
%	NULL
%	NULL
k	NULL
%	NULL
~	NULL
sok	NULL
kk	NULL
%	NULL
*kk*	NULL
%	NULL
%	NULL
%	NULL
%	NULL
%	NULL
GACTGCTG-GCAATTTCCC	NULL
GCTAAAGG	NULL
’	NULL
I	NULL
‘	NULL
G	NULL
’	NULL
I	NULL
‘	NULL
CTCAATACTCACTTTCAAGTC	NULL
CTAATCAAAGAGTGCCTTGCCTTCTCACAGCTGTAGACTACCGTTTTGA	NULL
1543	NULL
-50	NULL
CATGqTqTCqt	NULL
I	NULL
*	NULL
k	NULL
%	NULL
x	NULL
``	NULL
%	NULL
Kb	NULL
CACAGTCTGGC	NULL
it	NULL
*	NULL
%	NULL
%	NULL
k	NULL
%	NULL
[	NULL
rTACaCGE	NULL
+1	NULL
CGAGAGAGC	NULL
TGC	NULL
’	NULL
I	NULL
‘	NULL
GCCAC	NULL
’	NULL
I	NULL
‘	NULL
GC	NULL
’	NULL
I	NULL
‘	NULL
GCTAC	NULL
a	NULL
ﬂ	NULL
ACACAGCAGGGAGAAGCCCTAGTGCCTCTGC	NULL
x	NULL
x	NULL
*	NULL
%	NULL
[	NULL
e	NULL
ce	NULL
we	NULL
hee	NULL
ek	NULL
ne	NULL
h	NULL
e	NULL
e	NULL
e	NULL
k	NULL
&	NULL
*	NULL
%	NULL
%	NULL
*	NULL
K	NULL
de	NULL
dak	NULL
Bac	NULL
CAGAGAGCTGC	NULL
TGC	NULL
CAC	NULL
TGT	NULL
’	NULL
I	NULL
‘	NULL
GCT-	NULL
-	NULL
AGACACTGCAGGGAGAGCCCCCTGCACCGCTGC	NULL
+51	NULL
CGGCTGCCCAGCACCTGCTATCGGCCCACAGACCAAGTCCTCCACAGAGGGCGAGCCAGCGTGGACAACAGCCAGCCCAG	NULL
de	NULL
oe	NULL
te	NULL
e	NULL
ae	NULL
hee	NULL
e	NULL
e	NULL
ie	NULL
oe	NULL
t	NULL
oe	NULL
e	NULL
e	NULL
oe	NULL
o	NULL
k	NULL
k	NULL
%	NULL
kk	NULL
&	NULL
mere	NULL
e	NULL
cee	NULL
e	NULL
e	NULL
ee	NULL
e	NULL
e	NULL
te	NULL
e	NULL
oe	NULL
e	NULL
e	NULL
te	NULL
e	NULL
ke	NULL
se	NULL
este	NULL
LA	NULL
LL	NULL
CTSCTGCCCAGCACCTGCAGCCAGCACGCAGACTTCATCCTCCACAGAAGGAGAGTCAAGGAGGAGT-~~-GCCAGCCCAG	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Comparison	NULL
of	NULL
5	NULL
'	NULL
sequences	NULL
of	NULL
human	NULL
and	NULL
murine	NULL
IL-16	NULL
genes	NULL
.	NULL

The	NULL
published	NULL
start	NULL
points	NULL
of	NULL
transcription	NULL
in	NULL
human	NULL
cells	NULL
are	NULL
shown	NULL
in	NULL
bold	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Nucleotide	NULL
+1	NULL
corresponds	NULL
to	NULL
the	NULL
first	NULL
transcription	NULL
start	NULL
site	NULL
of	NULL
the	NULL
human	NULL
gene	NULL
.	NULL

Identical	NULL
nucleotides	NULL
in	NULL
both	NULL
sequences	NULL
are	NULL
indicated	NULL
by	NULL
*	NULL
.	NULL

Deletions	NULL
indicated	NULL
by	NULL
dashes	NULL
were	NULL
introduced	NULL
to	NULL
obtain	NULL
the	NULL
highest	NULL
degree	NULL
of	NULL
homology	NULL
.	NULL

The	NULL
CAAT	NULL
box-like	NULL
sequences	NULL
around	NULL
positions	NULL
-98	NULL
and	NULL
-118	NULL
and	NULL
direct	NULL
repeats	NULL
around	NULL
+12	NULL
and	NULL
-25	NULL
are	NULL
overlined	NULL
,	NULL
the	NULL
dyad	NULL
symmetry	NULL
element	NULL
,	NULL
DSE	NULL
,	NULL
is	NULL
double-underlined	NULL
,	NULL
and	NULL
the	NULL
GABP	NULL
-binding	NULL
sites	NULL
are	NULL
boxed	NULL
.	NULL

fected	NULL
into	NULL
Jurkat	NULL
T	NULL
,	NULL
cells	NULL
which	NULL
express	NULL
considerable	NULL
amounts	NULL
of	NULL
pro-IL-16	NULL
,	NULL
and	NULL
HeLa	NULL
cells	NULL
,	NULL
which	NULL
express	NULL
IL-16	NULL
at	NULL
very	NULL
low	NULL
levels	NULL
(	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

34	NULL
,	NULL
the	NULL
fragments	NULL
-1048/+88	NULL
and	NULL
-408/+88	NULL
exhibited	NULL
a	NULL
distinct	NULL
promoter	NULL
activity	NULL
in	NULL
both	NULL
types	NULL
of	NULL
cells	NULL
,	NULL
being	NULL
4-	NULL
to	NULL
5-fold	NULL
stronger	NULL
in	NULL
Jurkat	NULL
cells	NULL
than	NULL
in	NULL
HeLa	NULL
cells	NULL
.	NULL

Deletion	NULL
of	NULL
5	NULL
'	NULL
nucleotides	NULL
up	NULL
to	NULL
the	NULL
CAAT	NULL
box-like	NULL
motifs	NULL
(	NULL
up	NULL
to	NULL
-133	NULL
)	NULL
resulted	NULL
in	NULL
a	NULL
50	NULL
%	NULL
decrease	NULL
and	NULL
the	NULL
removal	NULL
of	NULL
this	NULL
motifs	NULL
by	NULL
deletion	NULL
up	NULL
to	NULL
-90	NULL
in	NULL
a	NULL
further	NULL
strong	NULL
decrease	NULL
of	NULL
constitutive	NULL
promoter	NULL
activity	NULL
.	NULL

A	NULL
similar	NULL
strong	NULL
decrease	NULL
was	NULL
observed	NULL
after	NULL
deleting	NULL
the	NULL
3	NULL
'	NULL
region	NULL
between	NULL
positions	NULL
+3	NULL
and	NULL
+88	NULL
containing	NULL
the	NULL
Ets	NULL
element	NULL
at	NULL
+12	NULL
,	NULL
and	NULL
the	NULL
removal	NULL
of	NULL
sequences	NULL
between	NULL
-110	NULL
and	NULL
+88	NULL
abolished	NULL
any	NULL
promoter	NULL
activity	NULL
.	NULL

To	NULL
delineate	NULL
the	NULL
inducible	NULL
promoter	NULL
elements	NULL
,	NULL
transfected	NULL
Jurkat	NULL
cells	NULL
and	NULL
HeLa	NULL
cells	NULL
were	NULL
induced	NULL
with	NULL
phorbol	NULL
ester	NULL
for	NULL
20	NULL
h.	NULL
This	NULL
resulted	NULL
in	NULL
a	NULL
7-	NULL
to	NULL
8-fold	NULL
increase	NULL
of	NULL
luciferase	NULL
reporter	NULL
gene	NULL
expression	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
in	NULL
HeLa	NULL
cells	NULL
transfected	NULL
with	NULL
constructs	NULL
containing	NULL
the	NULL
IL-16	NULL
promoter	NULL
region	NULL
from	NULL
-90	NULL
to	NULL
+88	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
sequences	NULL
from	NULL
+4	NULL
to	NULL
+88	NULL
,	NULL
which	NULL
include	NULL
the	NULL
third	NULL
Ets-like	NULL
protein	NULL
binding	NULL
site	NULL
at	NULL
+12	NULL
decreased	NULL
the	NULL
inducibility	NULL
up	NULL
to	NULL
50	NULL
%	NULL
.	NULL

Because	NULL
removal	NULL
of	NULL
the	NULL
upstream	NULL
region	NULL
from	NULL
position	NULL
-1048	NULL
to	NULL
-90	NULL
did	NULL
not	NULL
change	NULL
the	NULL
inducibility	NULL
,	NULL
the	NULL
fragment	NULL
from	NULL
A	NULL
position	NULL
-90	NULL
to	NULL
+88	NULL
appears	NULL
to	NULL
harbor	NULL
all	NULL
sequence	NULL
motifs	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
IL-16	NULL
promoter	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
Binding	NULL
of	NULL
GABPa	NULL
and	NULL
-	NULL
to	NULL
the	NULL
Ets-Binding	NULL
Sites	NULL
of	NULL
Proximal	NULL
Promoter	NULL
Region	NULL
Contributes	NULL
to	NULL
the	NULL
IL-16	NULL
Promoter	NULL
Induction	NULL
.	NULL

The	NULL
DSE	NULL
of	NULL
the	NULL
distal	NULL
IL-2	NULL
enhancer	NULL
(	NULL
DSEq	NULL
.	NULL

;	NULL
)	NULL
is	NULL
bound	NULL
by	NULL
GABP	NULL
factors	NULL
(	NULL
20	NULL
)	NULL
,	NULL
suggesting	NULL
a	NULL
binding	NULL
of	NULL
these	NULL
factors	NULL
to	NULL
the	NULL
IL-16	NULL
DSE	NULL
(	NULL
DSEmis	NULL
)	NULL
as	NULL
well	NULL
.	NULL

To	NULL
test	NULL
this	NULL
assumption	NULL
,	NULL
nuclear	NULL
proteins	NULL
from	NULL
Jurkat	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
EMSAs	NULL
by	NULL
using	NULL
the	NULL
DSEs	NULL
from	NULL
the	NULL
IL-16	NULL
promoter	NULL
and	NULL
distal	NULL
IL-2	NULL
enhancer	NULL
as	NULL
probes	NULL
.	NULL

Very	NULL
similar	NULL
to	NULL
the	NULL
DSE	NULL
.	NULL

,	NULL
four	NULL
specific	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
generated	NULL
with	NULL
the	NULL
DSEn..14	NULL
which	NULL
we	NULL
designate	NULL
as	NULL
I	NULL
(	NULL
a	NULL
and	NULL
b	NULL
,	NULL
higher	NULL
and	NULL
lower	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
II	NULL
,	NULL
and	NULL
III	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

TPA	NULL
treatment	NULL
of	NULL
cells	NULL
did	NULL
not	NULL
alter	NULL
their	NULL
appearance	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
formation	NULL
of	NULL
all	NULL
four	NULL
complexes	NULL
was	NULL
abolished	NULL
by	NULL
a	NULL
100-	NULL
and	NULL
200-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
unlabeled	NULL
probe	NULL
or	NULL
a	NULL
similar	NULL
excess	NULL
of	NULL
the	NULL
ERE-A	NULL
site	NULL
from	NULL
the	NULL
DSEy	NULL
.	NULL

,	NULL
.	NULL

;	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
and	NULL
the	NULL
SV40	NULL
enhancer	NULL
Ets	NULL
site	NULL
,	NULL
a	NULL
known	NULL
GABP	NULL
-binding	NULL
site	NULL
(	NULL
20	NULL
)	NULL
and	NULL
the	NULL
+12	NULL
Ets-like	NULL
site	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

44	NULL
,	NULL
lanes	NULL
3+4	NULL
,	NULL
7+8	NULL
,	NULL
9+10	NULL
,	NULL
and	NULL
15+16	NULL
)	NULL
.	NULL

The	NULL
competition	NULL
with	NULL
the	NULL
+12	NULL
site	NULL
indicates	NULL
that	NULL
this	NULL
site	NULL
is	NULL
an	NULL
additional	NULL
GABP	NULL
-binding	NULL
site	NULL
.	NULL

No	NULL
competition	NULL
was	NULL
observed	NULL
when	NULL
the	NULL
same	NULL
excess	NULL
was	NULL
used	NULL
of	NULL
a	NULL
DSEy.,14	NULL
mutated	NULL
in	NULL
both	NULL
Ets	NULL
motifs	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
,	NULL
lanes	NULL
5+6	NULL
)	NULL
or	NULL
of	NULL
binding	NULL
sites	NULL
for	NULL
NF-AT	NULL
,	NULL
AP-1	NULL
and	NULL
NF-KB	NULL
factors	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
,	NULL
lanes	NULL
11-14	NULL
,	NULL
17+18	NULL
)	NULL
.	NULL

B	NULL
160	NULL
7	NULL
MR	NULL
Jurkat	NULL
[	NULL
-	NULL
]	NULL
Hela	NULL
120	NULL
7	NULL
40	NULL
7	NULL
Luciferase-activity	NULL
,	NULL
fold	NULL
over	NULL
vector	NULL
so	NULL
E	NULL
O1	NULL
17/801	NULL
Ob-	NULL
AS	NULL
&	NULL
Ro	NULL
&	NULL
4	NULL
s	NULL
S	NULL
8	NULL
3	NULL
€	NULL
§	NULL
§	NULL
?	NULL

&	NULL
£	NULL
+	NULL
&	NULL
T	NULL
&	NULL
-	NULL
&	NULL
8	NULL
&	NULL
#	NULL
8	NULL
&	NULL
10	NULL
W	NULL
Jurkat	NULL
9	NULL
[	NULL
7	NULL
]	NULL
Hela	NULL
Fold	NULL
activation	NULL
by	NULL
TPA	NULL
treatment	NULL
a	NULL
88+/8901	NULL
88+/5€	NULL
1	NULL
$	NULL
8+/06	NULL
£+/66€°	NULL
OF-AS	NULL
88+/5€1~	NULL
Ot-	NULL
AS	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Promoter	NULL
activity	NULL
of	NULL
5	NULL
``	NULL
sequences	NULL
from	NULL
the	NULL
human	NULL
IL-16	NULL
gene	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
and	NULL
HeLa	NULL
cells	NULL
.	NULL

The	NULL
numbers	NULL
below	NULL
indicate	NULL
the	NULL
sequences	NULL
of	NULL
DNA	NULL
fragments	NULL
cloned	NULL
in	NULL
front	NULL
of	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
a	NULL
pGL3	NULL
vector	NULL
(	NULL
Promega	NULL
)	NULL
containing	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
is	NULL
also	NULL
shown	NULL
.	NULL

(	NULL
4	NULL
)	NULL
Deletion	NULL
analysis	NULL
of	NULL
the	NULL
5	NULL
``	NULL
IL-16	NULL
DNA	NULL
.	NULL

Relative	NULL
luciferase	NULL
activities	NULL
are	NULL
given	NULL
as	NULL
fold	NULL
activity	NULL
above	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
promoter-less	NULL
pGL3-Basic	NULL
vector	NULL
.	NULL

The	NULL
standard	NULL
deviations	NULL
represent	NULL
the	NULL
mean	NULL
values	NULL
from	NULL
four	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
B	NULL
)	NULL
TPA-mediated	NULL
induction	NULL
of	NULL
5	NULL
'	NULL
segments	NULL
of	NULL
IL-16	NULL
gene	NULL
.	NULL

Differences	NULL
of	NULL
luciferase	NULL
activities	NULL
are	NULL
shown	NULL
between	NULL
uninduced	NULL
cells	NULL
and	NULL
cells	NULL
treated	NULL
with	NULL
10	NULL
nM	NULL
TPA	NULL
and	NULL
indicated	NULL
as	NULL
``	NULL
Fold	NULL
activation	NULL
.	NULL
``	NULL

The	NULL
standard	NULL
deviations	NULL
represent	NULL
the	NULL
mean	NULL
values	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

1544	NULL
Immunology	NULL
:	NULL
Bannert	NULL
et	NULL
al	NULL
.	NULL

A	NULL
)	NULL
C	NULL
)	NULL
DSE-probe	NULL
|t.2	NULL
I-16	NULL
Extract	NULL
wok	NULL
k	NULL
k	NULL
22	NULL
Competi	NULL
casen	NULL
raze	NULL
ant	NULL
Pyoor	NULL
Antibody	NULL
|	NULL
-	NULL
a	NULL
$	NULL
afeuia	NULL
$	NULL
ng	NULL
-	NULL
|-	NULL
25	NULL
50	NULL
25	NULL
5o'25	NULL
sols	NULL
so	NULL
2550-25	NULL
50	NULL
2s	NULL
5025	NULL
50	NULL
-	NULL
‘	NULL
SS	NULL
|	NULL
»	NULL
l	NULL
La	NULL
we	NULL
uo	NULL
we	NULL
as	NULL
w	NULL
Le	NULL
II	NULL
*	NULL
II	NULL
P	NULL
“	NULL
wie	NULL
wss	NULL
as	NULL
Pid	NULL
#	NULL
»	NULL
#	NULL
»	NULL
IIl	NULL
»	NULL
#	NULL
»	NULL
#	NULL
>	NULL
#	NULL
#	NULL
PJ	NULL
due	NULL
~	NULL
>	NULL
dil	NULL
ane	NULL
d	NULL
dl	NULL
ie	NULL
c	NULL
m	NULL
i	NULL
ce	NULL
i	NULL
t	NULL
M	NULL
was	NULL
ane	NULL
te	NULL
ins	NULL
te	NULL
ae	NULL
ws	NULL
is	NULL
te	NULL
i	NULL
as	NULL
a	NULL
tt	NULL
wns	NULL
th	NULL
#	NULL
LJ	NULL
®	NULL
P	NULL
1234567	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
910	NULL
M213M415	NULL
1617	NULL
18	NULL
a	NULL
2	NULL
*	NULL
eRED	NULL
10	NULL
_|	NULL
‘	NULL
i	NULL
;	NULL
CCAGAGCGAAGGACRARTGTGGTGTCCTTCCCTCTCTCG	NULL
;	NULL
II	NULL
»	NULL
ERE-C	NULL
IL-2	NULL
462	NULL
ERE-A	NULL
4®	NULL
ps	NULL
424	NULL
III	NULL
rcHAACAGGAAACCAATACACTTCCTGT®TAATCAA	NULL
*	NULL
lat	NULL
ue	NULL
TTTGTCCTTIGSTTATGTGAAGGACAAATTAGTT	NULL
ERE-B	NULL
1	NULL
2	NULL
3456	NULL
7	NULL
fi	NULL
on	NULL
orm	NULL
ine	NULL
.	NULL

am	NULL
as..	NULL
l	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

-	NULL
GABP	NULL
factors	NULL
bind	NULL
to	NULL
the	NULL
Ets-like	NULL
sequence	NULL
motifs	NULL
of	NULL
IL-16	NULL
promoter	NULL
.	NULL

(	NULL
4	NULL
)	NULL
EMSAs	NULL
using	NULL
nuclear	NULL
proteins	NULL
from	NULL
Jurkat	NULL
cells	NULL
and	NULL
the	NULL
DSE	NULL
from	NULL
the	NULL
IL-16	NULL
promoter	NULL
as	NULL
probe	NULL
.	NULL

Two	NULL
micrograms	NULL
of	NULL
nuclear	NULL
protein	NULL
from	NULL
noninduced	NULL
Jurkat	NULL
cells	NULL
was	NULL
incubated	NULL
either	NULL
with	NULL
the	NULL
DSEn	NULL
.	NULL

;	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
DSEn.16	NULL
(	NULL
lanes	NULL
2-18	NULL
)	NULL
as	NULL
probes	NULL
(	NULL
see	NULL
B	NULL
)	NULL
followed	NULL
by	NULL
electrophoresis	NULL
on	NULL
a	NULL
native	NULL
4	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

For	NULL
competi-tion	NULL
,	NULL
25	NULL
and	NULL
50	NULL
ng	NULL
of	NULL
the	NULL
following	NULL
oligonucleotides	NULL
were	NULL
added	NULL
:	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
,	NULL
DSE	NULL
,	NULL
16	NULL
;	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
,	NULL
DSEn.14	NULL
mutated	NULL
in	NULL
both	NULL
Ets	NULL
motifs	NULL
;	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
,	NULL
IL-16	NULL
Ets	NULL
motif	NULL
at	NULL
position	NULL
+12	NULL
;	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
,	NULL
IL-2	NULL
ERE-A	NULL
motif	NULL
(	NULL
see	NULL
B	NULL
)	NULL
;	NULL
lanes	NULL
11	NULL
and	NULL
12	NULL
,	NULL
distal	NULL
NF-AT	NULL
site	NULL
from	NULL
the	NULL
murine	NULL
IL-2	NULL
promoter	NULL
(	NULL
see	NULL
ref	NULL
.	NULL

22	NULL
)	NULL
;	NULL
lanes	NULL
13	NULL
and	NULL
14	NULL
,	NULL
AP-1	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
22	NULL
)	NULL
;	NULL
lanes	NULL
15	NULL
and	NULL
16	NULL
,	NULL
Ets	NULL
site	NULL
from	NULL
the	NULL
SV40	NULL
enhancer	NULL
(	NULL
20	NULL
)	NULL
;	NULL
lanes	NULL
17	NULL
and	NULL
18	NULL
,	NULL
consensus	NULL
NF-KB	NULL
site	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Sequences	NULL
of	NULL
DSEs	NULL
from	NULL
the	NULL
IL-16	NULL
promoter	NULL
and	NULL
distal	NULL
IL-2	NULL
enhancer	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
palindromic	NULL
organization	NULL
of	NULL
Ets-related	NULL
elements	NULL
,	NULL
ERESs	NULL
,	NULL
is	NULL
indicated	NULL
in	NULL
gray	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Supershift	NULL
EMSAs	NULL
with	NULL
Abs	NULL
raised	NULL
against	NULL
GABPa	NULL
and	NULL
-	NULL
.	NULL

In	NULL
lanes	NULL
1-5	NULL
,	NULL
1	NULL
ug	NULL
of	NULL
nuclear	NULL
protein	NULL
from	NULL
Jurkat	NULL
cells	NULL
was	NULL
incubated	NULL
with	NULL
the	NULL
DSEn.146	NULL
probe	NULL
,	NULL
alone	NULL
or	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
Ab	NULL
raised	NULL
against	NULL
GABPa	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
-	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
or	NULL
with	NULL
both	NULL
Abs	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
a	NULL
Pu.1-specific	NULL
Ab	NULL
was	NULL
added	NULL
in	NULL
lane	NULL
5	NULL
.	NULL

In	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
,	NULL
the	NULL
DSE	NULL
.	NULL

16	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
Abs	NULL
alone	NULL
.	NULL

SS	NULL
,	NULL
complexes	NULL
supershifted	NULL
by	NULL
GABP	NULL
Abs	NULL
.	NULL

(	NULL
DD	NULL
)	NULL
Binding	NULL
of	NULL
recombinant	NULL
GABPa	NULL
and	NULL
-B	NULL
to	NULL
the	NULL
DSEn.16	NULL
.	NULL

Bacterially	NULL
expressed	NULL
GABPa	NULL
or	NULL
-B	NULL
(	NULL
2.5-20	NULL
ng	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
a	NULL
DSEp..14	NULL
probe	NULL
as	NULL
indicated	NULL
.	NULL

I-III	NULL
indicate	NULL
DNA-protein	NULL
complexes	NULL
identical	NULL
in	NULL
mobility	NULL
to	NULL
those	NULL
generated	NULL
with	NULL
nuclear	NULL
proteins	NULL
from	NULL
Jurkat	NULL
cells	NULL
(	NULL
4	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
GABP	NULL
proteins	NULL
in	NULL
the	NULL
IL-16	NULL
DSE	NULL
complexes	NULL
,	NULL
EMSA	NULL
supershift	NULL
assays	NULL
were	NULL
performed	NULL
by	NULL
using	NULL
Abs	NULL
raised	NULL
against	NULL
GABPa	NULL
and	NULL
-B	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4C	NULL
(	NULL
lanes	NULL
1-4	NULL
)	NULL
,	NULL
addition	NULL
of	NULL
these	NULL
Abs	NULL
resulted	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
several	NULL
``	NULL
supershift	NULL
complexes	NULL
``	NULL
at	NULL
the	NULL
expense	NULL
of	NULL
complexes	NULL
I	NULL
and	NULL
II	NULL
.	NULL

No	NULL
changes	NULL
in	NULL
complex	NULL
formation	NULL
were	NULL
observed	NULL
when	NULL
an	NULL
Ab	NULL
raised	NULL
against	NULL
Pu.1	NULL
,	NULL
another	NULL
factor	NULL
of	NULL
Ets	NULL
family	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
was	NULL
used	NULL
.	NULL

To	NULL
confirm	NULL
these	NULL
results	NULL
showing	NULL
GABP	NULL
proteins	NULL
in	NULL
the	NULL
DSE	NULL
complexes	NULL
,	NULL
increasing	NULL
concentrations	NULL
of	NULL
bacterially	NULL
expressed	NULL
recombinant	NULL
GABPa	NULL
and	NULL
-B	NULL
proteins	NULL
were	NULL
incubated	NULL
in	NULL
EMSAs	NULL
with	NULL
a	NULL
DSEn.14	NULL
probe	NULL
.	NULL

This	NULL
resulted	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
three	NULL
retarded	NULL
DNA-protein	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

4D	NULL
)	NULL
with	NULL
identical	NULL
mobilities	NULL
to	NULL
those	NULL
of	NULL
complexes	NULL
Ia	NULL
,	NULL
II	NULL
,	NULL
and	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
III	NULL
.	NULL

Whereas	NULL
the	NULL
rapidly	NULL
running	NULL
complex	NULL
III	NULL
was	NULL
generated	NULL
with	NULL
GABPa	NULL
alone	NULL
,	NULL
for	NULL
the	NULL
generation	NULL
of	NULL
complexes	NULL
Ia	NULL
and	NULL
II	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
both	NULL
GABPa	NULL
and	NULL
-B	NULL
was	NULL
necessary	NULL
indicating	NULL
the	NULL
presence	NULL
of	NULL
both	NULL
GABP	NULL
proteins	NULL
in	NULL
complexes	NULL
I	NULL
and	NULL
II	NULL
.	NULL

To	NULL
demonstrate	NULL
a	NULL
functional	NULL
role	NULL
for	NULL
GABPa	NULL
and	NULL
-	NULL
$	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
IL-16	NULL
promoter	NULL
,	NULL
we	NULL
transfected	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
controlled	NULL
by	NULL
the	NULL
IL-16	NULL
promoter	NULL
(	NULL
from	NULL
-408	NULL
to	NULL
+88	NULL
)	NULL
into	NULL
Jurkat	NULL
and	NULL
293	NULL
cells	NULL
alone	NULL
or	NULL
with	NULL
vectors	NULL
expressing	NULL
GABPa	NULL
and	NULL
-B	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

54	NULL
,	NULL
both	NULL
GABP	NULL
proteins	NULL
alone	NULL
exerted	NULL
a	NULL
moderate	NULL
stimulatory	NULL
effect	NULL
on	NULL
both	NULL
the	NULL
constitutive	NULL
and	NULL
TPA-induced	NULL
promoter	NULL
activity	NULL
,	NULL
which	NULL
was	NULL
significantly	NULL
enhanced	NULL
when	NULL
both	NULL
proteins	NULL
were	NULL
expressed	NULL
28	NULL
,	NULL
,	NULL
|	NULL
*	NULL
>	NULL
z8	NULL
2G	NULL
140	NULL
£	NULL
3	NULL
6C	NULL
G	NULL
a	NULL
x	NULL
—L	NULL
C	NULL
®	NULL
8g120	NULL
|	NULL
82	NULL
E	NULL
o	NULL
2	NULL
£§1m	NULL
£5	NULL
5g	NULL
w	NULL
)	NULL
|	NULL
§¢	NULL
_	NULL
]	NULL
~*	NULL
G	NULL
co	NULL
Nuse	NULL
J	NULL
ADNF-Ate	NULL
p300-N|	NULL
p300-M	NULL
p300-C	NULL
203	NULL
113.205	NULL
|	NULL
1.508	NULL
|_7éa-1871	NULL
|	NULL
1572-2370	NULL
a	NULL
[	NULL
P	NULL
whla	NULL
[	NULL
p	NULL
wh	NULL
a	NULL
|	NULL
P	NULL
wp	NULL
a	NULL
)	NULL
p	NULL
op	NULL
NC	NULL
tn	NULL
>	NULL
pe	NULL
<	NULL
4GABPq	NULL
8	NULL
%	NULL
Me	NULL
GABP	NULL
;	NULL
1023	NULL
4	NULL
56	NULL
7	NULL
#	NULL
ns	NULL
Luciferase	NULL
activity	NULL
(	NULL
Rel	NULL
.	NULL

units	NULL
x1000	NULL
)	NULL
No	NULL
[	NULL
=	NULL
]	NULL
aa	NULL
o	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

GABPa	NULL
and	NULL
-6	NULL
stimulate	NULL
,	NULL
in	NULL
concert	NULL
with	NULL
p300	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
IL-16	NULL
promoter	NULL
.	NULL

(	NULL
4	NULL
)	NULL
GABPa	NULL
and	NULL
-	NULL
stimulate	NULL
the	NULL
IL-16	NULL
promoter	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
controlled	NULL
by	NULL
the	NULL
IL-16	NULL
promoter	NULL
(	NULL
from	NULL
-408	NULL
to	NULL
+88	NULL
)	NULL
,	NULL
SRSPA-based	NULL
vectors	NULL
expressing	NULL
GABPa	NULL
or	NULL
-B	NULL
,	NULL
or	NULL
both	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
left	NULL
untreated	NULL
or	NULL
stimulated	NULL
with	NULL
TPA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
for	NULL
24	NULL
h.	NULL
(	NULL
B	NULL
)	NULL
The	NULL
GABP	NULL
-binding	NULL
sites	NULL
within	NULL
the	NULL
IL-16	NULL
promoter	NULL
are	NULL
of	NULL
crucial	NULL
importance	NULL
for	NULL
its	NULL
activity	NULL
.	NULL

Human	NULL
293	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
wild-type	NULL
IL-16	NULL
promoter	NULL
/luciferase	NULL
gene	NULL
construct	NULL
or	NULL
mutated	NULL
IL-16	NULL
promoter/	NULL
luciferase	NULL
constructs	NULL
alone	NULL
or	NULL
together	NULL
with	NULL
vectors	NULL
expressing	NULL
GABPa	NULL
and	NULL
-B.	NULL
CmDm	NULL
,	NULL
mutations	NULL
in	NULL
the	NULL
ERE-C	NULL
and	NULL
ERE-D	NULL
motifs	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
;	NULL
INIm	NULL
,	NULL
mutations	NULL
within	NULL
the	NULL
+12	NULL
GABP	NULL
site	NULL
which	NULL
overlaps	NULL
the	NULL
transcriptional	NULL
initiation	NULL
site	NULL
.	NULL

(	NULL
C	NULL
)	NULL
CBP/p300	NULL
enhance	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
IL-16	NULL
promoter	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
.	NULL

293	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
controlled	NULL
by	NULL
the	NULL
IL-16	NULL
promoter	NULL
(	NULL
from	NULL
-408	NULL
to	NULL
+88	NULL
)	NULL
and	NULL
0-50	NULL
ng	NULL
of	NULL
a	NULL
p300	NULL
expression	NULL
vector	NULL
as	NULL
indicated	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Interaction	NULL
between	NULL
GABPa	NULL
and	NULL
p300	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
bacterially	NULL
expressed	NULL
glutathione	NULL
S-transferase/p300	NULL
fusion	NULL
proteins	NULL
spanning	NULL
N-terminal	NULL
,	NULL
middle	NULL
,	NULL
or	NULL
C-terminal	NULL
portions	NULL
of	NULL
p300	NULL
immobilized	NULL
on	NULL
glutathione	NULL
agrose	NULL
beads	NULL
were	NULL
incubated	NULL
with	NULL
500	NULL
ng	NULL
of	NULL
bacterially	NULL
expressed	NULL
GABPa	NULL
,	NULL
-6	NULL
or	NULL
-	NULL
«	NULL
+f	NULL
.	NULL

The	NULL
bound	NULL
proteins	NULL
were	NULL
eluted	NULL
and	NULL
immunodetected	NULL
by	NULL
using	NULL
a	NULL
mix	NULL
of	NULL
GABPa+	NULL
B-specific	NULL
Abs	NULL
.	NULL

As	NULL
a	NULL
control	NULL
for	NULL
p300/GABP	NULL
interaction	NULL
,	NULL
a	NULL
glutathione	NULL
S-transferase	NULL
fusion	NULL
protein	NULL
containing	NULL
the	NULL
N-terminal	NULL
transacting	NULL
domain	NULL
of	NULL
NF-ATe	NULL
(	NULL
TADNF-ATe	NULL
,	NULL
113-205	NULL
)	NULL
was	NULL
used	NULL
.	NULL

In	NULL
lane	NULL
13	NULL
,	NULL
50	NULL
ug	NULL
of	NULL
nuclear	NULL
proteins	NULL
from	NULL
293	NULL
cells	NULL
were	NULL
fractionated	NULL
.	NULL

The	NULL
appearance	NULL
of	NULL
a	NULL
weak	NULL
GABPa	NULL
band	NULL
in	NULL
lane	NULL
11	NULL
is	NULL
the	NULL
result	NULL
of	NULL
an	NULL
accidental	NULL
contamination	NULL
of	NULL
the	NULL
GABPB	NULL
protein	NULL
preparation	NULL
with	NULL
GABPa	NULL
.	NULL

The	NULL
appearance	NULL
of	NULL
a	NULL
second	NULL
GABPa	NULL
band	NULL
in	NULL
many	NULL
lanes	NULL
is	NULL
probably	NULL
a	NULL
GABPa	NULL
cleavage	NULL
product	NULL
.	NULL

The	NULL
lowest	NULL
strong	NULL
band	NULL
is	NULL
most	NULL
likely	NULL
the	NULL
result	NULL
of	NULL
the	NULL
crossreactivity	NULL
of	NULL
GABP	NULL
Abs	NULL
with	NULL
a	NULL
bacterial	NULL
protein	NULL
binding	NULL
unspecifically	NULL
to	NULL
p300	NULL
.	NULL

Immunology	NULL
:	NULL
Bannert	NULL
et	NULL
al	NULL
.	NULL

together	NULL
.	NULL

Mutations	NULL
in	NULL
the	NULL
GABP	NULL
sites	NULL
ERE-C	NULL
and	NULL
-D	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
,	NULL
which	NULL
abolished	NULL
any	NULL
GABP	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
,	NULL
lanes	NULL
5+6	NULL
)	NULL
reduced	NULL
significantly	NULL
the	NULL
stimulatory	NULL
effect	NULL
of	NULL
GABP	NULL
proteins	NULL
on	NULL
the	NULL
constitutive	NULL
and	NULL
inducible	NULL
activity	NULL
of	NULL
IL-16	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
CmDm	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
+12	NULL
GABP	NULL
site	NULL
,	NULL
alone	NULL
or	NULL
together	NULL
with	NULL
the	NULL
CmDm	NULL
mutations	NULL
,	NULL
suppressed	NULL
any	NULL
promoter	NULL
induction	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
INIm	NULL
and	NULL
CmDm+INIm	NULL
)	NULL
,	NULL
indicating	NULL
a	NULL
critical	NULL
role	NULL
for	NULL
this	NULL
site	NULL
in	NULL
the	NULL
control	NULL
of	NULL
promoter	NULL
activity	NULL
.	NULL

The	NULL
Cofactors	NULL
CBP/p300	NULL
Bind	NULL
to	NULL
GABP	NULL
Proteins	NULL
and	NULL
Enhance	NULL
the	NULL
Induction	NULL
of	NULL
IL-16	NULL
Promoter	NULL
.	NULL

Ets-1	NULL
,	NULL
the	NULL
prototype	NULL
of	NULL
Ets	NULL
factors	NULL
,	NULL
was	NULL
shown	NULL
to	NULL
cooperate	NULL
with	NULL
the	NULL
nuclear	NULL
coactivators	NULL
CBP	NULL
/p300	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
CBP	NULL
/	NULL
p300	NULL
plays	NULL
a	NULL
similar	NULL
role	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
IL-16	NULL
promoter	NULL
by	NULL
GABP	NULL
factors	NULL
,	NULL
increasing	NULL
amounts	NULL
of	NULL
vectors	NULL
expressing	NULL
p300	NULL
or	NULL
CBP	NULL
were	NULL
cotransfected	NULL
into	NULL
293	NULL
cells	NULL
with	NULL
the	NULL
luciferase	NULL
reporter	NULL
gene	NULL
controlled	NULL
by	NULL
the	NULL
IL-16	NULL
promoter	NULL
.	NULL

Overexpress-ing	NULL
p300	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
or	NULL
CBP	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
resulted	NULL
in	NULL
a	NULL
dose-dependent	NULL
increase	NULL
in	NULL
the	NULL
constitutive	NULL
and	NULL
inducible	NULL
IL-16	NULL
promoter	NULL
activity	NULL
,	NULL
suggesting	NULL
that	NULL
this	NULL
cofactor	NULL
participates	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-16	NULL
promoter	NULL
.	NULL

To	NULL
demonstrate	NULL
that	NULL
the	NULL
GABP	NULL
factors	NULL
are	NULL
the	NULL
targets	NULL
of	NULL
p300-mediated	NULL
activation	NULL
of	NULL
the	NULL
IL-16	NULL
promoter	NULL
,	NULL
binding	NULL
of	NULL
p300	NULL
to	NULL
GABP	NULL
proteins	NULL
was	NULL
tested	NULL
.	NULL

Bacterially	NULL
expressed	NULL
,	NULL
full-length	NULL
GABPa	NULL
and	NULL
-	NULL
were	NULL
incubated	NULL
with	NULL
GST	NULL
/p300	NULL
proteins	NULL
spanning	NULL
large	NULL
portions	NULL
of	NULL
the	NULL
N-terminal	NULL
,	NULL
central	NULL
,	NULL
and	NULL
C-terminal	NULL
regions	NULL
of	NULL
p300	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5D	NULL
,	NULL
GABPa	NULL
bound	NULL
specifically	NULL
to	NULL
the	NULL
C-terminal	NULL
part	NULL
of	NULL
p300	NULL
and	NULL
much	NULL
more	NULL
weakly	NULL
to	NULL
its	NULL
N-terminal	NULL
part	NULL
.	NULL

No	NULL
binding	NULL
to	NULL
the	NULL
N-terminal	NULL
transactivation	NULL
domain	NULL
of	NULL
NF-ATe	NULL
(	NULL
TAD-NFATc	NULL
)	NULL
used	NULL
as	NULL
negative	NULL
control	NULL
was	NULL
observed	NULL
.	NULL

GABP	NULL
$	NULL
was	NULL
only	NULL
found	NULL
in	NULL
the	NULL
GST	NULL
/p300-bound	NULL
fraction	NULL
when	NULL
incubated	NULL
together	NULL
with	NULL
GABPa	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
,	NULL
lane	NULL
12	NULL
)	NULL
,	NULL
indicating	NULL
an	NULL
indirect	NULL
,	NULL
GABPa-mediated	NULL
recruitment	NULL
of	NULL
GABPB	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
a	NULL
direct	NULL
interaction	NULL
between	NULL
GABPa	NULL
and	NULL
the	NULL
C-terminal	NULL
part	NULL
of	NULL
p300	NULL
.	NULL

DISCUSSION	NULL
In	NULL
this	NULL
study	NULL
we	NULL
have	NULL
described	NULL
the	NULL
structure	NULL
of	NULL
the	NULL
human	NULL
IL-16	NULL
gene	NULL
,	NULL
including	NULL
its	NULL
promoter	NULL
.	NULL

The	NULL
IL-16	NULL
gene	NULL
consists	NULL
of	NULL
seven	NULL
exons	NULL
.	NULL

Exons	NULL
II-VII	NULL
encode	NULL
the	NULL
pro-IL-16	NULL
precursor	NULL
protein	NULL
,	NULL
whereas	NULL
the	NULL
mature	NULL
IL-16	NULL
is	NULL
encoded	NULL
by	NULL
sequences	NULL
of	NULL
the	NULL
last	NULL
three	NULL
exons	NULL
.	NULL

The	NULL
IL-16	NULL
gene	NULL
is	NULL
almost	NULL
exclusively	NULL
expressed	NULL
in	NULL
lymphocytes	NULL
and	NULL
epidermis	NULL
cells	NULL
of	NULL
the	NULL
respiratory	NULL
tract	NULL
after	NULL
allergic	NULL
stimulation	NULL
(	NULL
4	NULL
,	NULL
25	NULL
,	NULL
26	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
lymphocytes	NULL
by	NULL
antigens	NULL
,	NULL
PHA	NULL
,	NULL
and	NULL
other	NULL
mitogens	NULL
strongly	NULL
increases	NULL
the	NULL
transcription	NULL
of	NULL
IL-16	NULL
(	NULL
1	NULL
,	NULL
10	NULL
)	NULL
.	NULL

We	NULL
have	NULL
identified	NULL
the	NULL
immediate	NULL
upstream	NULL
region	NULL
of	NULL
the	NULL
IL-16	NULL
gene	NULL
(	NULL
reaching	NULL
up	NULL
to	NULL
nucleotide	NULL
position	NULL
-90	NULL
)	NULL
,	NULL
along	NULL
with	NULL
the	NULL
first	NULL
88	NULL
bp	NULL
of	NULL
the	NULL
untranslated	NULL
mRNA	NULL
region	NULL
,	NULL
as	NULL
the	NULL
most	NULL
important	NULL
DNA	NULL
fragment	NULL
for	NULL
the	NULL
control	NULL
of	NULL
inducible	NULL
expression	NULL
of	NULL
IL-16	NULL
gene	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

This	NULL
region	NULL
contains	NULL
three	NULL
GGAA	NULL
core	NULL
motifs	NULL
for	NULL
the	NULL
binding	NULL
of	NULL
Ets-like	NULL
factors	NULL
around	NULL
the	NULL
positions	NULL
-39	NULL
,	NULL
-25	NULL
,	NULL
and	NULL
+12	NULL
.	NULL

The	NULL
two	NULL
upstream	NULL
sites	NULL
at	NULL
-39	NULL
and	NULL
-25	NULL
form	NULL
a	NULL
33-bp	NULL
DSE	NULL
that	NULL
resembles	NULL
the	NULL
DSE	NULL
motifs	NULL
within	NULL
a	NULL
distal	NULL
IL-2	NULL
enhancer	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
and	NULL
the	NULL
CD18	NULL
promoter	NULL
.	NULL

As	NULL
shown	NULL
previously	NULL
for	NULL
GABP	NULL
binding	NULL
to	NULL
the	NULL
DSE	NULL
of	NULL
the	NULL
distal	NULL
IL-2	NULL
enhancer	NULL
(	NULL
20	NULL
)	NULL
the	NULL
GABP	NULL
proteins	NULL
a	NULL
and	NULL
B	NULL
are	NULL
the	NULL
most	NULL
prominent	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
DSE	NULL
of	NULL
IL-16	NULL
promoter	NULL
in	NULL
nuclear	NULL
protein	NULL
extracts	NULL
from	NULL
T	NULL
cells	NULL
.	NULL

Because	NULL
the	NULL
introduction	NULL
of	NULL
mutations	NULL
into	NULL
these	NULL
GABP	NULL
binding	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
reduced	NULL
significantly	NULL
the	NULL
induction	NULL
of	NULL
promoter	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

54	NULL
)	NULL
,	NULL
one	NULL
has	NULL
to	NULL
conclude	NULL
that	NULL
the	NULL
binding	NULL
of	NULL
GABP	NULL
factors	NULL
to	NULL
both	NULL
sites	NULL
is	NULL
of	NULL
crucial	NULL
importance	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
IL-16	NULL
promoter	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

GABPa	NULL
and	NULL
-B	NULL
form	NULL
heterodimeric	NULL
(	NULL
-B	NULL
)	NULL
and	NULL
heterotet-rameric	NULL
(	NULL
a	NULL
,	NULL
-f3	NULL
;	NULL
)	NULL
complexes	NULL
when	NULL
they	NULL
bind	NULL
to	NULL
the	NULL
DSE	NULL
of	NULL
the	NULL
distal	NULL
IL-2	NULL
enhancer	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

The	NULL
same	NULL
heteromeric	NULL
complexes	NULL
were	NULL
generated	NULL
with	NULL
the	NULL
DSE.14	NULL
as	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
4	NULL
and	NULL
D	NULL
)	NULL
.	NULL

However	NULL
,	NULL
approximately	NULL
3-fold	NULL
more	NULL
tetrameric	NULL
than	NULL
dimeric	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
1545	NULL
complexes	NULL
were	NULL
formed	NULL
on	NULL
the	NULL
DSEn.14	NULL
than	NULL
DSEp	NULL
.	NULL

,	NULL
;	NULL
(	NULL
deter-mined	NULL
by	NULL
dividing	NULL
the	NULL
amount	NULL
of	NULL
tetrameric	NULL
complexes	NULL
by	NULL
that	NULL
of	NULL
dimeric	NULL
complexes	NULL
according	NULL
to	NULL
phosphoimager	NULL
data	NULL
,	NULL
see	NULL
also	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
in	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

This	NULL
may	NULL
be	NULL
caused	NULL
by	NULL
the	NULL
specific	NULL
structure	NULL
of	NULL
in	NULL
which	NULL
the	NULL
GGAA	NULL
core	NULL
sequences	NULL
,	NULL
although	NULL
forming	NULL
a	NULL
palindrome	NULL
(	NULL
as	NULL
in	NULL
the	NULL
DSEp	NULL
.	NULL

,	NULL
;	NULL
)	NULL
are	NULL
not	NULL
directed	NULL
to	NULL
each	NULL
other	NULL
(	NULL
as	NULL
in	NULL
the	NULL
DSEn	NULL
.	NULL

,	NULL
;	NULL
)	NULL
but	NULL
are	NULL
directed	NULL
in	NULL
opposite	NULL
directions	NULL
.	NULL

This	NULL
configuration	NULL
appears	NULL
to	NULL
facilitate	NULL
the	NULL
formation	NULL
of	NULL
heterotetramers	NULL
,	NULL
probably	NULL
through	NULL
the	NULL
leucine	NULL
zipper	NULL
motifs	NULL
in	NULL
GABP	NULL
(	NULL
see	NULL
refs	NULL
.	NULL

27	NULL
and	NULL
28	NULL
for	NULL
a	NULL
discussion	NULL
)	NULL
and	NULL
appears	NULL
to	NULL
enhance	NULL
transcription	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
previously	NULL
for	NULL
the	NULL
activity	NULL
of	NULL
multiples	NULL
of	NULL
DSEn	NULL
.	NULL

,	NULL
;	NULL
that	NULL
the	NULL
generation	NULL
of	NULL
heterotetramers	NULL
gives	NULL
rise	NULL
to	NULL
a	NULL
strong	NULL
activation	NULL
of	NULL
transcription	NULL
compared	NULL
with	NULL
the	NULL
relatively	NULL
weak	NULL
activity	NULL
of	NULL
multiple	NULL
repeats	NULL
of	NULL
identical	NULL
EREs	NULL
to	NULL
which	NULL
GABPa	NULL
and	NULL
-B	NULL
bind	NULL
as	NULL
heterodimers	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
transcriptional	NULL
induction	NULL
of	NULL
IL-16	NULL
promoter	NULL
by	NULL
GABP	NULL
factors	NULL
is	NULL
distinctly	NULL
enhanced	NULL
by	NULL
the	NULL
cofactors	NULL
CBP/p300	NULL
,	NULL
which	NULL
interact	NULL
with	NULL
GABPa	NULL
(	NULL
Fig	NULL
.	NULL

5D	NULL
)	NULL
.	NULL

CBP	NULL
and	NULL
p300	NULL
are	NULL
nuclear	NULL
proteins	NULL
that	NULL
were	NULL
shown	NULL
to	NULL
bind	NULL
to	NULL
and	NULL
to	NULL
increase	NULL
the	NULL
activity	NULL
of	NULL
numerous	NULL
transcription	NULL
factors	NULL
by	NULL
exerting	NULL
adaptor	NULL
functions	NULL
and	NULL
histone	NULL
acetylase	NULL
activity	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
they	NULL
provide	NULL
a	NULL
molecular	NULL
platform	NULL
for	NULL
a	NULL
large	NULL
number	NULL
of	NULL
potentially	NULL
important	NULL
associated	NULL
proteins	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
several	NULL
inducible	NULL
transcription	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
AP-1/c-Jun	NULL
,	NULL
NF-kB/p65	NULL
,	NULL
and	NULL
the	NULL
NF-AT	NULL
factors	NULL
NF-ATp	NULL
and	NULL
c	NULL
,	NULL
that	NULL
are	NULL
activated	NULL
after	NULL
lymphocyte	NULL
activation	NULL
,	NULL
were	NULL
shown	NULL
to	NULL
cooperate	NULL
with	NULL
CBP/	NULL
p300	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
.	NULL

For	NULL
NF-ATe	NULL
,	NULL
it	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
CBP/p300	NULL
is	NULL
able	NULL
to	NULL
synergize	NULL
with	NULL
multiple	NULL
protein	NULL
kinase	NULL
cascades	NULL
in	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
this	NULL
factor	NULL
.	NULL

This	NULL
may	NULL
also	NULL
be	NULL
true	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
GA	NULL
BPs	NULL
that	NULL
are	NULL
a	NULL
nuclear	NULL
target	NULL
of	NULL
Ras-Raf-Erk	NULL
and	NULL
JNK/SAP	NULL
kinase	NULL
cascades	NULL
(	NULL
21	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Although	NULL
a	NULL
direct	NULL
phosphorylation	NULL
of	NULL
GABPa	NULL
by	NULL
Erk2	NULL
has	NULL
been	NULL
demonstrated	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
(	NULL
33	NULL
)	NULL
,	NULL
the	NULL
phosphorylation	NULL
of	NULL
CBP	NULL
/p300	NULL
or	NULL
of	NULL
associated	NULL
proteins	NULL
by	NULL
these	NULL
mitogen-activated	NULL
protein	NULL
kinases	NULL
provides	NULL
a	NULL
further	NULL
level	NULL
of	NULL
regulation	NULL
through	NULL
which	NULL
the	NULL
induction	NULL
of	NULL
IL-16	NULL
promoter	NULL
by	NULL
GABP	NULL
factors	NULL
may	NULL
be	NULL
controlled	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
third	NULL
Ets-like	NULL
binding	NULL
site	NULL
at	NULL
position	NULL
+12	NULL
appears	NULL
to	NULL
be	NULL
a	NULL
further	NULL
GABP-binding	NULL
site	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
region	NULL
containing	NULL
this	NULL
site	NULL
decreased	NULL
both	NULL
the	NULL
constitutive	NULL
and	NULL
inducible	NULL
activation	NULL
of	NULL
IL-16	NULL
promoter	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
.	NULL

Many	NULL
TATA-less	NULL
RNA	NULL
polymerase	NULL
II	NULL
promoters	NULL
contain	NULL
typical	NULL
initiator	NULL
elements	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
short	NULL
conserved	NULL
sequences	NULL
that	NULL
are	NULL
bound	NULL
by	NULL
proteins	NULL
of	NULL
the	NULL
transcriptional	NULL
machinery	NULL
.	NULL

Some	NULL
of	NULL
these	NULL
promoters	NULL
,	NULL
including	NULL
the	NULL
CD3s	NULL
,	NULL
CD4	NULL
,	NULL
CD11ec	NULL
,	NULL
CD18	NULL
,	NULL
CD72	NULL
,	NULL
IL-2R	NULL
$	NULL
,	NULL
TGF	NULL
RII	NULL
,	NULL
Ets-2	NULL
,	NULL
murine	NULL
laminin	NULL
B2	NULL
,	NULL
type	NULL
IV	NULL
colla-genase	NULL
,	NULL
thymidylate	NULL
synthetase	NULL
,	NULL
and	NULL
cytochrome	NULL
c	NULL
oxidase	NULL
subunit	NULL
IV	NULL
promoters	NULL
possess	NULL
Ets-like	NULL
binding	NULL
motifs	NULL
near	NULL
their	NULL
transcriptional	NULL
start	NULL
sites	NULL
,	NULL
suggesting	NULL
a	NULL
new	NULL
class	NULL
of	NULL
initiator	NULL
elements	NULL
(	NULL
34-45	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
two	NULL
PEA3	NULL
motifs	NULL
that	NULL
are	NULL
bound	NULL
by	NULL
GABP	NULL
factors	NULL
were	NULL
shown	NULL
to	NULL
function	NULL
as	NULL
a	NULL
minimal	NULL
transcriptional	NULL
initiator	NULL
element	NULL
when	NULL
placed	NULL
in	NULL
front	NULL
of	NULL
a	NULL
luciferase	NULL
gene	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
+12	NULL
GABP	NULL
binding	NULL
site	NULL
of	NULL
IL-16	NULL
promoter	NULL
might	NULL
act	NULL
as	NULL
a	NULL
similar	NULL
initiator	NULL
element	NULL
starting	NULL
transcription	NULL
from	NULL
the	NULL
TATA-less	NULL
IL-16	NULL
gene	NULL
.	NULL

The	NULL
CAAT	NULL
box-like	NULL
sequences	NULL
located	NULL
between	NULL
-133	NULL
and	NULL
-90	NULL
are	NULL
needed	NULL
for	NULL
the	NULL
full	NULL
IL-16	NULL
promoter	NULL
activity	NULL
in	NULL
both	NULL
Jurkat	NULL
T	NULL
cells	NULL
and	NULL
HeLa	NULL
cells	NULL
.	NULL

Additional	NULL
positively	NULL
acting	NULL
sequence	NULL
element	NULL
(	NULL
s	NULL
)	NULL
is/are	NULL
located	NULL
in	NULL
the	NULL
region	NULL
between	NULL
-408	NULL
and	NULL
-133	NULL
,	NULL
because	NULL
deletion	NULL
of	NULL
this	NULL
segment	NULL
leads	NULL
to	NULL
a	NULL
50	NULL
%	NULL
decrease	NULL
of	NULL
promoter	NULL
activity	NULL
.	NULL

However	NULL
,	NULL
the	NULL
sequence	NULL
elements	NULL
and	NULL
the	NULL
transcription	NULL
factors	NULL
binding	NULL
to	NULL
and	NULL
controlling	NULL
the	NULL
activity	NULL
of	NULL
these	NULL
elements	NULL
remain	NULL
to	NULL
be	NULL
identified	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
the	NULL
structure	NULL
of	NULL
the	NULL
inducible	NULL
IL-16	NULL
promoter	NULL
differs	NULL
markedly	NULL
from	NULL
that	NULL
of	NULL
typical	NULL
interleukin	NULL
promoters	NULL
(	NULL
such	NULL
as	NULL
the	NULL
IL-2	NULL
and	NULL
IL-4	NULL
promoters	NULL
)	NULL
,	NULL
which	NULL
are	NULL
predominantly	NULL
activated	NULL
on	NULL
antigen-mediated	NULL
stimulation	NULL
in	NULL
peripheral	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

It	NULL
will	NULL
be	NULL
interesting	NULL
to	NULL
determine	NULL
the	NULL
1546	NULL
Immunology	NULL
:	NULL
Bannert	NULL
et	NULL
al	NULL
.	NULL

physiological	NULL
differences	NULL
reflected	NULL
in	NULL
the	NULL
architecture	NULL
of	NULL
these	NULL
two	NULL
types	NULL
of	NULL
lymphokine	NULL
promoters	NULL
.	NULL

We	NULL
thank	NULL
Olga	NULL
Reimers	NULL
and	NULL
Martin	NULL
Selbert	NULL
for	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

For	NULL
gifts	NULL
of	NULL
reagents	NULL
we	NULL
are	NULL
very	NULL
much	NULL
indebted	NULL
to	NULL
Drs	NULL
.	NULL

Angelika	NULL
Hoffmeyer	NULL
,	NULL
Egbert	NULL
Flory	NULL
,	NULL
and	NULL
Richard	NULL
Eckner	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
Dr.	NULL
Steve	NULL
Norley	NULL
for	NULL
help	NULL
in	NULL
the	NULL
preparation	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

Parts	NULL
of	NULL
this	NULL
work	NULL
were	NULL
supported	NULL
by	NULL
Grant	NULL
1506/TGO4	NULL
from	NULL
the	NULL
Federal	NULL
Ministry	NULL
of	NULL
Health	NULL
and	NULL
the	NULL
Heinz	NULL
Kuthe	NULL
de	NULL
Mouson	NULL
legacy	NULL
(	NULL
to	NULL
RK	NULL
.	NULL
)	NULL

and	NULL
the	NULL
SFB	NULL
465	NULL
(	NULL
Wiirzburg	NULL
)	NULL
(	NULL
to	NULL
E.S	NULL
.	NULL
)	NULL

.	NULL

1	NULL
.	NULL

2	NULL
.	NULL

3	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

Center	NULL
,	NULL
D.	NULL
M.	NULL
&	NULL
Cruikshank	NULL
,	NULL
W.	NULL
(	NULL
1982	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

128	NULL
,	NULL
2563-2568	NULL
.	NULL

Bazan	NULL
,	NULL
J.	NULL
F.	NULL
&	NULL
Schall	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
381	NULL
,	NULL
29-30	NULL
.	NULL

Bannert	NULL
,	NULL
N.	NULL
,	NULL
Baier	NULL
,	NULL
M.	NULL
,	NULL
Werner	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Kurth	NULL
,	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
381	NULL
,	NULL
30	NULL
.	NULL

Baier	NULL
,	NULL
M.	NULL
,	NULL
Bannert	NULL
,	NULL
N.	NULL
,	NULL
Werner	NULL
,	NULL
A.	NULL
,	NULL
Lang	NULL
,	NULL
K.	NULL
&	NULL
Kurth	NULL
,	NULL
R.	NULL
(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
,	NULL
5273-5277	NULL
.	NULL

Doyle	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Lee	NULL
,	NULL
A.	NULL
,	NULL
Lewis	NULL
,	NULL
J.	NULL
,	NULL
Kim	NULL
,	NULL
E.	NULL
,	NULL
Sheng	NULL
,	NULL
M.	NULL
&	NULL
Mac-Kinnon	NULL
,	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
Cell	NULL
85	NULL
,	NULL
1067-1076	NULL
.	NULL

Cho	NULL
,	NULL
K.	NULL
O.	NULL
,	NULL
Hunt	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

&	NULL
Kennedy	NULL
,	NULL
M.	NULL
B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Neuron	NULL
9	NULL
,	NULL
929-942	NULL
.	NULL

Zhang	NULL
,	NULL
Y.	NULL
,	NULL
Center	NULL
,	NULL
D.	NULL
,	NULL
Wu	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Cruikshank	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Yuan	NULL
,	NULL
J.	NULL
,	NULL
Andrews	NULL
,	NULL
D.	NULL
W.	NULL
&	NULL
Kornfeld	NULL
,	NULL
H.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273	NULL
,	NULL
1144-1149	NULL
.	NULL

Laberge	NULL
,	NULL
S.	NULL
,	NULL
Cruikshank	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Kornfeld	NULL
,	NULL
H.	NULL
&	NULL
Center	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

155	NULL
,	NULL
2902-2910	NULL
.	NULL

Laberge	NULL
,	NULL
S.	NULL
,	NULL
Cruikshank	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Beer	NULL
,	NULL
D.	NULL
J	NULL
.	NULL

&	NULL
Center	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

156	NULL
,	NULL
310-315	NULL
.	NULL

Rumsaeng	NULL
,	NULL
V.	NULL
,	NULL
Cruikshank	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Foster	NULL
,	NULL
B.	NULL
,	NULL
Prussin	NULL
,	NULL
C.	NULL
,	NULL
Kirshenbaum	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Davis	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
Kornfeld	NULL
,	NULL
H.	NULL
,	NULL
Center	NULL
,	NULL
D.	NULL
M.	NULL
&	NULL
Metcalfe	NULL
,	NULL
D.	NULL
D.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

159	NULL
,	NULL
2904-2910	NULL
.	NULL

Cruikshank	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Center	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Nisar	NULL
,	NULL
N.	NULL
,	NULL
Wu	NULL
,	NULL
M.	NULL
,	NULL
Natke	NULL
,	NULL
B.	NULL
,	NULL
Theodore	NULL
,	NULL
A.	NULL
C.	NULL
&	NULL
Kornfeld	NULL
,	NULL
H.	NULL
(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91	NULL
,	NULL
5109-5113	NULL
.	NULL

Center	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Kornfeld	NULL
,	NULL
H.	NULL
&	NULL
Cruikshank	NULL
,	NULL
W.	NULL
W.	NULL
(	NULL
1996	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
17	NULL
,	NULL
476-481	NULL
.	NULL

Cruikshank	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Lim	NULL
,	NULL
K.	NULL
,	NULL
Theodore	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Cook	NULL
,	NULL
J.	NULL
,	NULL
Fine	NULL
,	NULL
G.	NULL
,	NULL
Weller	NULL
,	NULL
P.	NULL
F.	NULL
&	NULL
Center	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

157	NULL
,	NULL
5240-5248	NULL
.	NULL

Parada	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
Center	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Kornfeld	NULL
,	NULL
H.	NULL
,	NULL
Rodriguez	NULL
,	NULL
W.	NULL
L.	NULL
,	NULL
Cook	NULL
,	NULL
J.	NULL
,	NULL
Vallen	NULL
,	NULL
M.	NULL
&	NULL
Cruikshank	NULL
,	NULL
W.	NULL
W.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

160	NULL
,	NULL
2115-2120	NULL
.	NULL

Baier	NULL
,	NULL
M.	NULL
,	NULL
Werner	NULL
,	NULL
A.	NULL
,	NULL
Bannert	NULL
,	NULL
N.	NULL
,	NULL
Metzner	NULL
,	NULL
K.	NULL
&	NULL
Kurth	NULL
,	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
378	NULL
,	NULL
563	NULL
.	NULL

Zhou	NULL
,	NULL
P.	NULL
,	NULL
Goldstein	NULL
,	NULL
S.	NULL
,	NULL
Devadas	NULL
,	NULL
K.	NULL
,	NULL
Tewari	NULL
,	NULL
D.	NULL
&	NULL
Notkins	NULL
,	NULL
A.	NULL
L.	NULL
(	NULL
1997	NULL
)	NULL
Nat	NULL
.	NULL

Med	NULL
.	NULL

3	NULL
,	NULL
659-664	NULL
.	NULL

Idziorek	NULL
,	NULL
T.	NULL
,	NULL
Khalife	NULL
,	NULL
O.	NULL
,	NULL
Billaut-Mulot	NULL
,	NULL
E.	NULL
,	NULL
Hermann	NULL
,	NULL
M.	NULL
,	NULL
Aumercier	NULL
,	NULL
M.	NULL
&	NULL
Mouton	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Clin	NULL
.	NULL

Exp	NULL
.	NULL

Immunol	NULL
.	NULL

112	NULL
,	NULL
84-91	NULL
.	NULL

Bisset	NULL
,	NULL
L.	NULL
R.	NULL
,	NULL
Rothen	NULL
,	NULL
M.	NULL
,	NULL
Joller-Jemelka	NULL
,	NULL
H.	NULL
I.	NULL
,	NULL
Dubs	NULL
,	NULL
R.	NULL
W.	NULL
,	NULL
Grob	NULL
,	NULL
P.	NULL
J	NULL
.	NULL

&	NULL
Opravil	NULL
,	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
AIDS	NULL
11	NULL
,	NULL
485-491	NULL
.	NULL

Bannert	NULL
,	NULL
N.	NULL
,	NULL
Adler	NULL
,	NULL
H.	NULL
S.	NULL
,	NULL
Werner	NULL
,	NULL
A.	NULL
,	NULL
Baier	NULL
,	NULL
M.	NULL
&	NULL
Kurth	NULL
,	NULL
R.	NULL
(	NULL
1998	NULL
)	NULL
Immunogenetics	NULL
47	NULL
,	NULL
390-397	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
Avots	NULL
,	NULL
A.	NULL
,	NULL
Hoffmeyer	NULL
,	NULL
A.	NULL
,	NULL
Flory	NULL
,	NULL
E.	NULL
,	NULL
Cimanis	NULL
,	NULL
A.	NULL
,	NULL
Rapp	NULL
,	NULL
U.	NULL
R.	NULL
&	NULL
Serfling	NULL
,	NULL
E.	NULL
(	NULL
1997	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17	NULL
,	NULL
4381-4389	NULL
.	NULL

Hoffmeyer	NULL
,	NULL
A.	NULL
,	NULL
Avots	NULL
,	NULL
A.	NULL
,	NULL
Flory	NULL
,	NULL
E.	NULL
,	NULL
Weber	NULL
,	NULL
C.	NULL
K.	NULL
,	NULL
Serfling	NULL
,	NULL
E.	NULL
&	NULL
Rapp	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273	NULL
,	NULL
10112-10119	NULL
.	NULL

Serfling	NULL
,	NULL
E.	NULL
,	NULL
Avots	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Neumann	NULL
,	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1263	NULL
,	NULL
181-200	NULL
.	NULL

Janknecht	NULL
,	NULL
R.	NULL
&	NULL
Hunter	NULL
,	NULL
T.	NULL
(	NULL
1996	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
383	NULL
,	NULL
22-23	NULL
.	NULL

Yang	NULL
,	NULL
C.	NULL
,	NULL
Shapiro	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
Rivera	NULL
,	NULL
M.	NULL
,	NULL
Kumar	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Brindle	NULL
P.	NULL
K.	NULL
(	NULL
1998	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
2218-2229	NULL
.	NULL

Laberge	NULL
,	NULL
S.	NULL
,	NULL
Ernst	NULL
,	NULL
P.	NULL
,	NULL
Ghaffar	NULL
,	NULL
O.	NULL
,	NULL
Cruikshank	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Kornfeld	NULL
,	NULL
H.	NULL
,	NULL
Center	NULL
,	NULL
D.	NULL
M.	NULL
&	NULL
Hamid	NULL
,	NULL
Q	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Respir	NULL
.	NULL

Cell	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

17	NULL
,	NULL
193-202	NULL
.	NULL

Hessel	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
Cruikshank	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Van	NULL
Ark	NULL
,	NULL
L.	NULL
,	NULL
De	NULL
Bie	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Van	NULL
Esch	NULL
,	NULL
B.	NULL
,	NULL
Hofman	NULL
,	NULL
G.	NULL
,	NULL
Nijkamp	NULL
,	NULL
F.	NULL
P.	NULL
,	NULL
Center	NULL
,	NULL
D.	NULL
M.	NULL
&	NULL
Van	NULL
Oosterhout	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

160	NULL
,	NULL
2998-3005	NULL
.	NULL

Batchelor	NULL
,	NULL
A.	NULL
H.	NULL
,	NULL
Piper	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
de	NULL
la	NULL
Brousse	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
McKnight	NULL
,	NULL
S.	NULL
L.	NULL
&	NULL
Wolberger	NULL
,	NULL
C.	NULL
(	NULL
1998	NULL
)	NULL
Science	NULL
279	NULL
,	NULL
1037-1041	NULL
.	NULL

Graves	NULL
,	NULL
B.	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Science	NULL
279	NULL
,	NULL
1000-1001	NULL
.	NULL

Eckner	NULL
,	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

377	NULL
,	NULL
685-688	NULL
.	NULL

Torchia	NULL
,	NULL
J.	NULL
,	NULL
Glass	NULL
,	NULL
C.	NULL
&	NULL
Rosenfeld	NULL
,	NULL
M.	NULL
G.	NULL
(	NULL
1998	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

10	NULL
,	NULL
373-383	NULL
.	NULL

Gerritsen	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Williams	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Neish	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
Moore	NULL
,	NULL
S.	NULL
,	NULL
Shi	NULL
,	NULL
Y	NULL
.	NULL

&	NULL
Collins	NULL
,	NULL
T.	NULL
(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94	NULL
,	NULL
2927-2932	NULL
.	NULL

Lee	NULL
,	NULL
J.-S.	NULL
,	NULL
See	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
Deng	NULL
,	NULL
T.	NULL
&	NULL
Shi	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16	NULL
,	NULL
4312-4326	NULL
.	NULL

Flory	NULL
,	NULL
E.	NULL
,	NULL
Hoffmeyer	NULL
,	NULL
A.	NULL
,	NULL
Smola	NULL
,	NULL
U.	NULL
,	NULL
Rapp	NULL
,	NULL
U.	NULL
R.	NULL
&	NULL
Bruder	NULL
,	NULL
J.	NULL
T.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

70	NULL
,	NULL
2260-2268	NULL
.	NULL

Clevers	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
Dunlap	NULL
,	NULL
S.	NULL
,	NULL
Wileman	NULL
,	NULL
T.	NULL
E.	NULL
&	NULL
Terhorst	NULL
,	NULL
C.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85	NULL
,	NULL
8156-8160	NULL
.	NULL

Salmon	NULL
,	NULL
P.	NULL
,	NULL
Giovane	NULL
,	NULL
A.	NULL
,	NULL
Wasylyk	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Klatzmann	NULL
,	NULL
D.	NULL
(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
,	NULL
7739-7743	NULL
.	NULL

Bottinger	NULL
,	NULL
E.	NULL
P.	NULL
,	NULL
Shelley	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
Farokhzad	NULL
,	NULL
O.	NULL
C.	NULL
&	NULL
Arnaout	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
2604-2615	NULL
.	NULL

Rosmarin	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
Caprio	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
Kirsch	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
Handa	NULL
,	NULL
H.	NULL
&	NULL
Simkevich	NULL
,	NULL
C.	NULL
P.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
23627-23633	NULL
.	NULL

Ying	NULL
,	NULL
H.	NULL
,	NULL
Chang	NULL
,	NULL
J.	NULL
F.	NULL
&	NULL
Parnes	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

160	NULL
,	NULL
2287-2296	NULL
.	NULL

Lin	NULL
,	NULL
J.	NULL
X.	NULL
,	NULL
Bhat	NULL
,	NULL
N.	NULL
K.	NULL
,	NULL
John	NULL
,	NULL
S.	NULL
,	NULL
Queale	NULL
,	NULL
W.	NULL
S.	NULL
&	NULL
Leonard	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
,	NULL
6201-6210	NULL
.	NULL

Markiewicz	NULL
,	NULL
S.	NULL
,	NULL
Bosselut	NULL
,	NULL
R.	NULL
,	NULL
Le	NULL
Deist	NULL
,	NULL
F.	NULL
,	NULL
de	NULL
Villartay	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Hivroz	NULL
,	NULL
C.	NULL
,	NULL
Ghysdael	NULL
,	NULL
J.	NULL
,	NULL
Fischer	NULL
,	NULL
A	NULL
.	NULL

&	NULL
de	NULL
Saint	NULL
Basile	NULL
,	NULL
G.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
14849-14855	NULL
.	NULL

Mavrothalassitis	NULL
,	NULL
G.	NULL
J	NULL
.	NULL

&	NULL
Papas	NULL
,	NULL
T.	NULL
S.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

2	NULL
,	NULL
215-224	NULL
.	NULL

Ogawa	NULL
,	NULL
K.	NULL
,	NULL
Burbelo	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
Sasaki	NULL
,	NULL
M.	NULL
&	NULL
Yamada	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

263	NULL
,	NULL
8384-8389	NULL
.	NULL

Huhtala	NULL
,	NULL
P.	NULL
,	NULL
Chow	NULL
,	NULL
L.	NULL
T.	NULL
&	NULL
Tryggvason	NULL
,	NULL
K.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
11077-11082	NULL
.	NULL

Jolliff	NULL
,	NULL
K.	NULL
,	NULL
Li	NULL
,	NULL
Y	NULL
.	NULL

&	NULL
Johnson	NULL
,	NULL
L.	NULL
F.	NULL
(	NULL
1991	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19	NULL
,	NULL
2267-2274	NULL
.	NULL

Virbasius	NULL
,	NULL
J.	NULL
V.	NULL
&	NULL
Scarpulla	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
5631-5638	NULL
.	NULL

Yu	NULL
,	NULL
M.	NULL
,	NULL
Yang	NULL
,	NULL
X.	NULL
Y.	NULL
,	NULL
Schmidt	NULL
,	NULL
T.	NULL
,	NULL
Chinenov	NULL
,	NULL
Y.	NULL
,	NULL
Wang	NULL
,	NULL
R.	NULL
&	NULL
Martin	NULL
,	NULL
M.	NULL
E.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
29060-29067	NULL
.	NULL

